WO2012103493A1 - Composés du benzopyran comme modificateurs de la mélanogenèse et utilisations associées - Google Patents

Composés du benzopyran comme modificateurs de la mélanogenèse et utilisations associées Download PDF

Info

Publication number
WO2012103493A1
WO2012103493A1 PCT/US2012/022994 US2012022994W WO2012103493A1 WO 2012103493 A1 WO2012103493 A1 WO 2012103493A1 US 2012022994 W US2012022994 W US 2012022994W WO 2012103493 A1 WO2012103493 A1 WO 2012103493A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
compound
melanogenesis
alkyl
Prior art date
Application number
PCT/US2012/022994
Other languages
English (en)
Inventor
Seth J. Orlow
Original Assignee
New York University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University filed Critical New York University
Publication of WO2012103493A1 publication Critical patent/WO2012103493A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Definitions

  • the present invention relates to the identification of benzopyran compounds that modulate melanin synthesis (melanogenesis), and the use of such compounds and compositions thereof to modify (e.g., inhibit) melanin production.
  • This invention also relates to methods for preventing and/or treating conditions that are causally related to aberrant melanogenesis activity, such as comprising (but not limited to) pigmentation abnormalities and hyperpigmentation, using the compounds of the invention. It is to be understood that such compounds may be used either alone or in combination with other compounds having the activity set forth herein.
  • melanosomes synthesize melanin inside specialized organelles called melanosomes
  • Melanosomes are formed by the fusion of two types of vesicles.
  • Melanin is a dark biological pigment (biochrome) found in the skin, hair, feathers, scales, eyes, and some internal membranes of many animals that confers protection against ultraviolet radiation. See
  • the ability to control melanin synthesis may be used advantageously to address a variety of health-related conditions, as well as cosmetic objectives. Decreasing pigmentation is a desirable outcome in the treatment of disorders such as melasma, chloasma, post-inflammatory hyperpigmentation, solar lentigines, and the like.
  • hydroquinone a well known active substance for skin de-pigmentation, as described in U.S. Patent No. 6,139,854.
  • Hydroquinone can, however, have serious side effects if applied over a long period of time.
  • the application of hydroquinone to skin may, for example, lead to permanent de-pigmentation, which results in increased photosensitivity of the skin upon exposure to ultraviolet light.
  • Hydroquinone can be
  • cortisone which can thin the skin and cause other problems following facial administration
  • retinoic acid an irritant
  • glycolic acid an irritant
  • WO 99/64025 describes compositions for skin lightening which contain tyrosinase inhibiting extracts from dicotyledonous plant species indigenous to Canada.
  • U.S. Patent No. 5,580,549 describes an external preparation for skin lightening comprising 2-hydroxybenzoic acid derivatives and salts thereof as inhibitors of tyrosinase.
  • WO 99/09011 describes an agent for inhibiting skin erythema and/or skin pigmentation, containing at least one carbostyril derivative and salts thereof.
  • Manga describes methods for identifying compounds that alter melanogenesis in melanogenic cells, more particularly, compounds that inhibit or enhance P protein function. This method is based, in part, on the observation that P protein function is required for proper cellular localization of tyrosinase and other melanosomal proteins, and is required for both full tyrosinase activity and melanogenesis in melanogenic cell types.
  • Orlow et al. describe screens for identifying compounds that inhibit or increase melanogenesis in melanogenic cells. See WO 01 1131. These studies were based upon the discovery that some compounds that inhibit melanogenesis do so by causing a mislocalization of tyrosinase, the key enzyme in melanin synthesis.
  • U.S. Patent No. 5,352,440 for example, is directed to increasing melanin synthesis in melanocytes and increasing pigmentation by administration of certain diacylglycerol compounds.
  • U.S. Patent No. 5,532,001 is directed to increasing pigmentation in mammalian skin via administration of certain DNA fragments.
  • U.S. Patent No. 5,554,359 is directed to increasing levels of melanin in melanocytes by administration of lysosomotropic agents.
  • U.S. Patent Nos. 6, 750,229 and 6,995,804 are directed to the identification of protease-activated receptor-2 (PAR- 2) pathway and nitric oxide synthesis modulators, respectively, and their use in modulating pigmentation levels.
  • PAR-2 protease-activated receptor-2
  • the present invention is directed to compounds that may be identified by cell- based assays, which compounds control melanogenesis.
  • compounds were screened in cell-based assays to identify compounds capable of controlling, and particularly, inhibiting melanogenesis. Details pertaining to the screening assays are described in the Examples below.
  • the results of the screening assays identified a plurality of compounds that modify (i.e. inhibit) melanogenesis, some of which were not previously known to exhibit such activity and others of which are known to affect melanogenesis.
  • the confirmation of the activity of known modifiers of melanogenesis in the present screen corroborates the validity of the techniques and experimental approach.
  • inventions directed to the identification of previously unidentified benzopyran melanogenesis inhibitors, and their use in controlling (e.g. reducing) pigmentation in in vitro and in vivo applications.
  • the disclosure further provides methods of administering the benzopyran melanogenesis inhibitors as an extract, or as a purified compound.
  • the method optionally includes obtaining a quantity of plant matter from a plant of the osage family, optionally comminuting the plant matter, contacting said plant matter with an extraction medium, and separating the plant matter from the extraction medium.
  • novel melanogenesis modifiers include compounds represented by formula I:
  • R 3 is selected from H, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted aryl; and substituted or unsubstituted heteroaryl;
  • R 4 is selected from H, halo, hydroxy, alkoxy, alkenyloxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, and substituted or unsubstituted phenyl;
  • each R 5 , R 6 ' and R 8 is independently selected from H, halo, hydroxy, alkoxy, alkenyloxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, and substituted or unsubstituted phenyl;
  • R 6 and R 7 or R 7 and R 8 are joined to form a 5- or 6- membered heterocycloalkyl or heterocycloalkenyl; and the heterocycloalkyl or heterocycloalkenyl is unsubstituted or substituted with one more groups selected from alkyl, alkenyl, hydroxyalkyl, acyloxyalkyl, hydroxy, and alkoxy; or pharmaceutically acceptable salts, solvates, isomers, tautomers, metabolites, analogs, isotopic variants or prodrugs thereof.
  • Vllb (osajin-4'-methyl ether):
  • the compound is formula VIIc (pomiferin-3', 4 '-
  • Another aspect of the invention provides a method for preventing or inhibiting melanogenesis comprising administering an effective amount of a compound of formula I.
  • Another aspect of the invention provides a method for promoting skin lightening comprising administering an effective amount of a compound of formula I.
  • the invention provides methods for inhibiting melanogenesis using the compounds of formulae I-VIIc.
  • the invention provides methods for inhibiting melanogenesis using a plant extract containing compounds of formula I.
  • the plant extract is derived from the fruit of Madura pomifera.
  • the invention provides methods for promoting skin lightening using the compounds of formulae I-VIIc.
  • the invention provides methods for promoting skin lightening using a plant extract containing compounds of formula I.
  • the plant extract is derived from the fruit of Madura pomifera.
  • test-tube based and additional cell-based assays may be used to test the ability of modified versions and/or compounds to alter
  • melanogenesis In vivo applications are directed to the administration of at least one of the novel melanogenesis modifier compounds to a subject desirous thereof or in need thereof to control and/or to reduce pigmentation levels for prophylactic, therapeutic and/or cosmetic purposes.
  • compositions disclosed herein may contain one or more of the benzopyran compounds which have been identified as modifiers of melanogenesis.
  • the disclosed embodiments encompass a method for decreasing pigmentation in mammalian skin, hair or wool, and /or enhancing the brightening thereof, which comprises topically administering to the mammal an effective amount of one or more compounds described herein as a melanogenesis modifier.
  • a melanogenesis modifier as disclosed herein or a composition thereof may be applied to sites of hyperpigmentation including, without limitation, age spots, freckles, drug-induced hyperpigmentation, post-inflammatory hyperpigmentation as seen in acne, seborrheic keratoses, melasma and chloasma.
  • sites of hyperpigmentation including, without limitation, age spots, freckles, drug-induced hyperpigmentation, post-inflammatory hyperpigmentation as seen in acne, seborrheic keratoses, melasma and chloasma.
  • body whitening over a larger area of the skin is desirable and may be achieved with a more generalized application of a melanogenesis inhibitor disclosed herein or a composition thereof.
  • compositions including cosmetic formulations, comprising a compound or compounds disclosed herein, and a suitable biocompatible or bioinert carrier, excipient or diluent.
  • composition can comprise one or more of the compounds described herein.
  • the compounds disclosed herein are useful in cosmetic and/or pharmaceutical compositions and treatment methods disclosed herein, are all pharmaceutically and/or cosmetically acceptable as prepared and used.
  • compositions comprising a combination of a compound described herein with various additional compounds or agents, including compounds or agents that may have a like effect on melanogenesis, such as, for example, other skin lighteners, skin brightening agents or skin bleaching agents.
  • the additional compound or agent may be a skin care active agent, such as an abrasive, an absorbent, an astringent, an aesthetic component, such as fragrances, pigments, colorings/colorants, essential oils, skin sensates, astringents and other aesthetic components, an antioxidant, a reducing agent, a sequestrant, a skin bleaching or lightening agent, a skin conditioning agent, for example humectants and emollients, a skin soothing agent, a skin healing agent, such as pathenol and derivatives, aloe vera, pantothenic acid, allantoin, bisbolol, dipotassium glycyrrhizinate, skin treating agents, vitamins and derivatives, such as a retinoid, or mixtures thereof.
  • a skin care active agent such as an abrasive, an absorbent, an astringent, an aesthetic component, such as fragrances, pigments, colorings/colorants, essential oils, skin sensates, astring
  • the retinoid is retinol, retinal, retinol esters, retinyl propionate, retinoic acid, retinyl palmitate, or mixtures thereof.
  • the pharmaceutical and/or cosmetic compositions can comprise one or more of the compounds described herein.
  • the compounds are useful in the pharmaceutical and/or cosmetic compositions and treatment methods disclosed herein, are all pharmaceutically and/or cosmetically acceptable as prepared and used.
  • melanogenesis inhibitor is a benzopyran melanogenesis inhibitor as in Formula I.
  • the melanogenesis inhibitor is an osajin derivative, such as osajin-4'-methyl ether.
  • the melanogenesis inhibitor is pomiferin-3', 4 '-dimethyl ether or a pomiferin-3', 4 '-dimethyl ether derivative.
  • the melanocytes are mammalian melanocytes.
  • the skin tissue is human skin including but not limited to African American, Asian and Caucasian skin equivalents.
  • the plant extract is derived from a plant of the osage family. In some embodiments, the plant extract is derived from the fruit of Madura pomifera (osage orange).
  • the plant extract can be used as a
  • the plant extract is substantially purified or partially purified for concentration of the melanogenesis inhibitor.
  • the plant extract may be substantially liquefied or partially liquefied for administration to a patient in need thereof.
  • the plant extract may also be processed to remove particulate matter prior to administration.
  • the melanogenesis inhibitor is an osajin derivative, such as osajin-4' -methyl ether.
  • a topical formulation comprising a composition is provided for cosmetic and/or dermatological/pharmaceutical use, said
  • composition comprising a plant extract containing a prophylactically, cosmetically or
  • the plant extract is derived from a plant of the osage family. In some embodiments, the plant extract is derived from the fruit of Madura pomifera. In some embodiments, the plant extract is substantially purified or partially purified for concentration of the melanogenesis inhibitor. In other embodiments, the plant extract may be substantially liquefied or partially liquefied for administration to a patient in need thereof. The plant extract may also be processed to remove particulate matter prior to administration. In some
  • the melanogenesis inhibitor is an osajin derivative, such as osajin-4' -methyl ether.
  • the melanogenesis inhibitor is pomiferin-3 ',4 '-dimethyl ether or a pomiferin-3 ',4 '-dimethyl ether derivative.
  • Also provided are methods for preventing, treating, ameliorating or managing a disease or condition involving undesired or aberrant melanogenesis which comprises
  • the melanogenesis inhibitor is a benzopyran melanogenesis inhibitor as in Formula I.
  • the melanogenesis inhibitor is an osajin derivative, such as osajin-4 '-methyl ether.
  • the melanogenesis inhibitor is pomiferin-3 ',4 '-dimethyl ether or a pomiferin-3 ',4'- dimethyl ether derivative.
  • methods for altering or restoring pigmentation in mammalian skin, hair, wool or fur comprising administering to the mammalian skin, hair, wool or fur an amount, which is effective to alter or restore pigmentation in mammalian skin, hair, wool or fur, of a plant extract containing osajin.
  • methods of treatment of a mammal including a human being, to treat a disease for which a melanogenesis inhibitor is indicated, including treating said mammal with an effective amount of a plant extract containing osajin.
  • the plant extract is derived from a plant of the osage family.
  • the plant extract is derived from the fruit of Madura pomifera. In some embodiments, the plant extract is substantially purified or partially purified for concentration of the melanogenesis inhibitor. In other embodiments, the plant extract may be substantially liquefied or partially liquefied for administration to a patient in need thereof. The plant extract may also be processed to remove particulate matter prior to administration. In some embodiments, the melanogenesis inhibitor is an osajin derivative, such as osajin-4' -methyl ether.
  • the melanogenesis inhibitor is pomiferin-3', 4 '-dimethyl ether or a pomiferin-3', 4 '-dimethyl ether derivative.
  • the melanogenesis-inhibitor containing plant extract is administered to lighten or reduce pigmentation levels.
  • the melanogenesis-inhibitor-containing plant extract is administered to lighten or reduce pigmentation levels of hyperpigmented sites on skin.
  • the melanogenesis inhibitor is an osajin derivative, such as osajin-4'-methyl ether.
  • the melanogenesis inhibitor is pomiferin-3 ',4 '-dimethyl ether or a pomiferin-3 ',4 '-dimethyl ether derivative.
  • the plant extract is derived from a plant of the osage family.
  • the plant extract is derived from the fruit of Madura pomifera. In some embodiments, the plant extract is substantially purified or partially purified for concentration of the melanogenesis inhibitor. In other embodiments, the plant extract may be substantially liquefied or partially liquefied for administration to a patient in need thereof. The plant extract may also be processed to remove particulate matter prior to administration. In some
  • the melanogenesis inhibitor is an osajin derivative, such as osajin-4 '-methyl ether.
  • the melanogenesis inhibitor is pomiferin-3 ',4 '-dimethyl ether or a pomiferin-3 ',4 '-dimethyl ether derivative.
  • combinations of a plant extract as disclosed herein and a like-acting agent are provided.
  • the like acting agent can be selected from a cosmetic ingredient and/or a pharmacologically active agent.
  • the cosmetic ingredient may be a skin lightener or a sunscreen agent or an agent that increases skin cell turnover.
  • pharmacologically active agent can be selected from another melanogenesis inhibitor.
  • Another aspect encompasses a method for inhibiting melanogenesis by
  • melanocytes comprising administering to the melanocytes an effective amount of a plant extract containing a melanogenesis-inhibitor in combination with a like-acting agent.
  • the plant extract is substantially purified or partially purified for concentration of the melanogenesis inhibitor.
  • the plant extract may be substantially liquefied or partially liquefied for administration to a patient in need thereof.
  • the plant extract may also be processed to remove particulate matter prior to administration.
  • the melanogenesis inhibitor is an osajin derivative, such as osajin-4 '-methyl ether.
  • the melanogenesis inhibitor is pomiferin-3 ',4 '-dimethyl ether or a pomiferin-3 ',4 '-dimethyl ether derivative.
  • Also provided herein is a method for preventing, treating, ameliorating or managing a disease or condition involving undesired or aberrant melanogenesis, which comprises administering to a patient in need or desirous of such prevention, treatment, amelioration or management, a prophylactically or therapeutically effective melanogenesis-inhibiting amount of a plant extract in combination with a like-acting agent.
  • a mammal including a human being, to treat a disease for which a melanogenesis inhibitor is indicated, including treating said mammal with an effective amount of a plant extract containing a melanogenesis- inhibitor in combination with a like-acting agent.
  • the plant extract is derived from a plant of the osage family.
  • the plant extract is derived from the fruit of Madura pomifera.
  • methods for altering or restoring pigmentation in mammalian skin, hair, wool or fur comprising administering to the mammalian skin, hair, wool or fur an amount, which is effective to alter or restore pigmentation in mammalian skin, hair, wool or fur, of a plant extract containing a melanogenesis-inhibitor in combination with a like-acting agent.
  • the like acting agent can be selected from a cosmetic ingredient and a pharmacologically active agent.
  • a cosmetic ingredient is a skin lightener.
  • the pharmacologically active agent can be selected from another
  • FIGURE 1 is a graph of the results of individual dose-response testing of compounds of the invention as inhibitors of melanogenesis.
  • FIGURE 2 is a graph of the results of the MTT proliferation dose response testing of particular compounds of the invention.
  • FIGURE 3 is a graph of the results of the individual MTT proliferation dose response testing of Osajin.
  • FIGURE 4 is a graph of the results of the individual MTT proliferation dose response testing of Osajin-4' -methyl ether.
  • FIGURE 5 is a graph of the results of the individual MTT proliferation dose response testing of Pomiferin.
  • FIGURE 6 is a graph of the results of individual MTT proliferation dose response testing of Pomiferin-3', 4 '-dimethyl ether.
  • FIGURE 7 is a graph of the results of the individual MTT proliferation dose response testing of Warangalone.
  • Acyl refers to a group or radical -C(0)R 20 , where R 20 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloheteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl as defined herein.
  • Representative examples include, but are not limited to, formyl, acetyl, cylcohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl,
  • Acylamino refers to a group or radical -NR C(0)R , where R is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloheteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl and R 22 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloheteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted
  • Representative examples include, but are not limited to, formylamino, acetylamino, cyclohexylcarbonylamino, cyclohexylmethyl- carbonylamino, benzoylamino, benzylcarbonylamino and the like.
  • Acyloxy refers to the group or radical -OC(0)R 23 where R 23 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl or substituted or unsubstituted cycloalkyl.
  • Substituted alkenyl includes those groups recited in the definition of
  • substituted herein, and particularly refers to an alkenyl group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, hydroxyl, keto, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioketo, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl-S(0) 2 - and aryl-S(0) 2 -.
  • alkoxy refers to the group -OR 24 where R 24 is alkyl.
  • Particular alkoxy groups include, by way of example, substituted or unsubstituted methoxy, substituted or unsubstituted ethoxy, substituted or unsubstituted n-propoxy, substituted or unsubstituted isopropoxy, substituted or unsubstituted n-butoxy, substituted or unsubstituted tert-butoxy, substituted or unsubstituted sec-butoxy, substituted or unsubstituted n-pentoxy, substituted or unsubstituted n- hexoxy, substituted or unsubstituted 1 ,2-dimethylbutoxy, and the like.
  • substituted herein, and particularly refers to an alkoxy group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, heteroaryl, hydroxyl, keto, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioketo, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl-S(0) 2 - and aryl-S(0) 2 -.
  • substituents for instance from 1 to 5
  • Alkoxycarbonylamino refers to the group -N R 25 C(0)R 26 where R 25 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl or substituted or unsubstituted cycloalkyl, and R 26 is substituted or unsubstituted alkyl or substituted or unsubstituted cycloalkyl.
  • Alkyl refers to monovalent saturated alkane radical groups particularly having up to about 11 carbon atoms, more particularly as a lower alkyl, from 1 to 8 carbon atoms and still more particularly, from 1 to 6 carbon atoms.
  • the hydrocarbon chain may be either straight- chained or branched. This term is exemplified by groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, z ' so-butyl, tert-butyl, n-hexyl, n-octyl, tert-octyl and the like, and may be substituted or unsubstituted.
  • lower alkyl refers to alkyl groups having 1 to 6 carbon atoms.
  • alkyl also includes "cycloalkyls" as defined below.
  • Substituted alkyl includes those groups recited in the definition of "substituted” herein, and particularly refers to an alkyl group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, hydroxyl, heteroaryl, keto, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioketo, thiol, alkyl-S(O)-, aryl- S(O)-, alkyl
  • Alkylene refers to divalent saturated alkene radical groups having 1 to 1 1 carbon atoms and more particularly 1 to 6 carbon atoms which can be straight-chained or branched. This term is exemplified by groups such as substituted or unsubstituted methylene (- CH 2 -), substituted or unsubstituted ethylene (-CH 2 CH 2 -), the substituted or unsubstituted propylene isomers (e.g., -CH 2 CH 2 CH 2 - and -CH(CH 3 )CH 2 -) and the like.
  • Substituted alkylene includes those groups recited in the definition of
  • substituted herein, and particularly refers to an alkylene group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, halogen, hydroxyl, keto, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioketo, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl- S(0) 2 - and aryl-S(0) 2 -.
  • substituents for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, selected from the group consisting
  • Alkenyl refers to monovalent olefmically unsaturated hydrocarbyl groups preferably having 2 to 1 1 carbon atoms, particularly, from 2 to 8 carbon atoms, and more particularly, from 2 to 6 carbon atoms, which can be straight-chained or branched and having at least 1 and particularly from 1 to 2 sites of olefinic unsaturation.
  • Alkenylene refers to divalent olefmically unsaturated hydrocarbyl groups particularly having up to about 1 1 carbon atoms and more particularly 2 to 6 carbon atoms which can be straight-chained or branched and having at least 1 and particularly from 1 to 2 sites of olefinic unsaturation.
  • Alkynyl refers to acetylenically or alkynically unsaturated hydrocarbyl groups particularly having 2 to 1 1 carbon atoms and more particularly 2 to 6 carbon atoms which can be straight-chained or branched and having at least 1 and particularly from 1 to 2 sites of alkynyl unsaturation.
  • alkynyl groups include substituted or unsubstituted acetylenic, substituted or unsubstituted ethynyl (-C ⁇ CH), substituted or
  • Substituted alkynyl includes those groups recited in the definition of
  • substituted herein, and particularly refers to an alkynyl group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, hydroxyl, keto, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioketo, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl-S(0) 2 - and aryl-S(0) 2 -.
  • alkanoyl or "acyl” as used herein refers to the group R 27 -C(0)-, where R 27 is hydrogen or substituted or unsubstituted alkyl as defined above.
  • Aryl refers to a monovalent aromatic hydrocarbon group derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system.
  • Typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleia
  • Substituted Aryl includes those groups recited in the definition of "substituted” herein, and particularly refers to an aryl group that may optionally be substituted with 1 or more substituents, for instance from 1 to 5 substituents, particularly 1 to 3 substituents, selected from the group consisting of acyl, acylamino, acyloxy, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy, alkoxycarbonyl, alkyl, substituted alkyl, alkynyl, substituted alkynyl, amino, substituted amino, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, hydroxyl, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thiol, alkyl-
  • Fused Aryl refers to an aryl having two of its ring carbon in common with a second substituted or unsubstituted aryl ring or with a substituted or unsubstituted aliphatic ring.
  • Alkaryl refers to an aryl group, as defined above, substituted with one or more substituted or unsubstituted alkyl groups, as defined above.
  • alkyl or "arylalkyl” refers to an alkyl group, as defined above, substituted with one or more substituted or unsubstituted aryl groups, as defined above.
  • Aryloxy refers to substituted or unsubstituted -O-aryl groups wherein “aryl” is as defined above.
  • Alkylamino refers to the group alkyl-NR 28 R 29 , wherein each of R 28 and R 29 are independently selected from hydrogen and substituted or unsubstituted alkyl.
  • Arylamino refers to the group aryl-NR R , wherein each of R and R are independently selected from hydrogen, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
  • Alkoxyamino refers to a radical -N(H)OR 32 where R 32 represents a substituted or unsubstituted alkyl or substituted or unsubstituted cycloalkyl group as defined herein.
  • Alkoxycarbonyl refers to a substituted or unsubstituted radical -C(0)-alkoxy where alkoxy is as defined herein.
  • Alkylarylamino refers to a substituted or unsubstituted radical -NR 33 R 34 where
  • R 33 represents an alkyl or cycloalkyl group and R 34 is an aryl as defined herein.
  • Alkylsulfonyl refers to a substituted or unsubstituted radical -S(0) 2 R 35 where
  • R 35 is an alkyl or cycloalkyl group as defined herein. Representative examples include, but are not limited to, methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl and the like.
  • Alkylsulfmyl refers to a substituted or unsubstituted radical -S(0)R 35 where R 35 is an alkyl or cycloalkyl group as defined herein. Representative examples include, but are not limited to, methylsulfmyl, ethylsulfinyl, propylsulfmyl, butylsulfmyl and the like.
  • Alkylthio refers to a substituted or unsubstituted radical -SR 35 where R 35 is an alkyl or cycloalkyl group as defined herein that may be optionally substituted as defined herein.
  • Representative examples include, but are not limited to, methylthio, ethylthio, propylthio, butylthio, and the like.
  • Amino refers to the radical -NH 2 .
  • substituted herein, and particularly refers to the group -N(R 36 ) 2 where each R 36 is
  • both R groups are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, cycloalkyl, substituted cycloalkyl, and where both R groups are joined to form an alkylene group.
  • both R groups are hydrogen, - N(R 36 ) 2 is an amino group.
  • Aminocarbonyl refers to the group -C(0)NR 37 R 37 where each R 37 is
  • Aminocarbonylamino refers to the group -NR 38 C(0)NR 38 R 38 where each R 38 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl or substituted or unsubstituted cycloalkyl, or where two R groups are joined to form an alkylene group.
  • Aminocarbonyloxy refers to the group -OC(0)NR 39 R 39 where each R 39 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl or substituted or unsubstituted cycloalkyl, or where the R groups are joined to form an alkylene group.
  • Arylalkyloxy refers to a substituted or unsubstituted -O-arylalkyl radical where arylalkyl is as defined herein.
  • Arylamino means a substituted or unsubstituted radical -NHR 40 where R 40 represents an aryl group as defined herein.
  • Aryloxycarbonyl refers to a substituted or unsubstituted radical -C(0)-0-aryl where aryl is as defined herein.
  • Arylsulfonyl refers to a r substituted or unsubstituted phenomenonl -S(0) 2 R 41 where
  • R 41 is an aryl or heteroaryl group as defined herein.
  • Bicycloaryl refers to a monovalent aromatic hydrocarbon group derived by the removal of one hydrogen atom from a single carbon atom of a parent bicycloaromatic ring system.
  • Typical bicycloaryl groups include, but are not limited to, groups derived from indane, indene, naphthalene, tetrahydronaphthalene, and the like, and may be substituted or
  • an aryl group comprises from 8 to 11 carbon atoms.
  • Bicycloheteroaryl refers to a monovalent bicycloheteroaromatic group derived by the removal of one hydrogen atom from a single atom of a parent bicycloheteroaromatic ring system.
  • bicycloheteroaryl groups include, but are not limited to, groups derived from benzofuran, benzimidazole, benzindazole, benzdioxane, chromene, chromane, cinnoline, phthalazine, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, benzothiazole, benzoxazole, naphthyridine, benzoxadiazole, pteridine, purine, benzopyran, benzpyrazine, pyridopyrimidine, quinazoline, quinoline, quinolizine, quinoxaline, benzomorphan, tetrahydroisoquinoline, tetrahydroquinoline, and the like, and may be substituted or unsubstituted.
  • the bicycloheteroaryl group is between 9-11
  • bicycloheteroaryl with 5-10 membered heteroaryl being particularly preferred.
  • Particular bicycloheteroaryl groups are those derived from benzothiophene, benzofuran, benzothiazole, indole, quinoline, isoquinoline, benzimidazole, benzoxazole and benzdioxane.
  • Carbamoyl refers to the radical -C(0)N(R 42 ) 2 where each R 42 group is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted aryl, as defined herein, which may be optionally substituted as defined herein.
  • Carboxy refers to the radical -C(0)OH.
  • Carboxyamino refers to the radical -N(H)C(0)OH.
  • Cycloalkyl refers to cyclic hydrocarbyl groups having from 3 to about 10 carbon atoms and having a single cyclic ring or multiple condensed rings, including fused and bridged ring systems, which optionally can be substituted with from 1 to 3 alkyl groups.
  • Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, 1-methylcyclopropyl, 2-methylcyclopentyl, 2- methylcyclooctyl, and the like, and multiple ring structures such as adamantanyl, and the like, and may be substituted or unsubstituted.
  • substituted herein, and particularly refers to a cycloalkyl group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, hydroxyl, keto, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioketo, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl-S(0) 2 - and aryl-S(0) 2 -.
  • substituents for instance from 1 to 5
  • Cycloalkoxy refers to the group -OR 43 where R 43 is substituted or unsubstituted cycloalkyl.
  • Such cycloalkoxy groups include, by way of example, substituted or unsubstituted cyclopentoxy, substituted or unsubstituted cyclohexoxy and the like.
  • Cycloalkenyl refers to cyclic hydrocarbyl groups having from 3 to 10 carbon atoms and having a single cyclic ring or multiple condensed rings, including fused and bridged ring systems and having at least one and particularly from 1 to 2 sites of olefmic unsaturation.
  • Such cycloalkenyl groups include, by way of example, single ring structures such as substituted or unsubstituted cyclohexenyl, substituted or unsubstituted cyclopentenyl, substituted or unsubstituted cyclopropenyl, and the like.
  • Substituted cycloalkenyl includes those groups recited in the definition of
  • substituted herein, and particularly refers to a cycloalkenyl group having 1 or more
  • substituents for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl,
  • Fused Cycloalkenyl refers to a substituted or unsubstituted cycloalkenyl having two of its ring carbon atoms in common with a second aliphatic or aromatic ring and having its olefmic unsaturation located to impart aromaticity to the cycloalkenyl ring.
  • Cyclone refers to the radical -OCN.
  • Dialkylamino means a radical -NR 44 R 45 where R 44 and R 45 independently represent an alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroaryl, or substituted heteroaryl group as defined herein.
  • Ethylene refers to substituted or unsubstituted -(C-C)-.
  • Halo or "halogen” refers to fluoro, chloro, bromo and iodo. Preferred halo groups are either fluoro or chloro.
  • Haldroxy refers to the radical -OH.
  • Niro refers to the radical -N0 2 .
  • Substituted refers to a group in which one or more hydrogen atoms are each independently replaced with the same or different substituent(s).
  • R 50 and R 51 are independently hydrogen, alkyl, substituted alkyl, aryl, substituted alkyl, arylalkyl, substituted alkyl, cycloalkyl, substituted alkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl.
  • one of R and R may be hydrogen and at least one of R and
  • R 53 is each independently selected from alkyl, alkenyl, alkynyl, cycloheteroalkyl, alkanoyl, alkoxy, aryloxy, heteroaryloxy, alkylamino, arylamino, heteroarylamino, NR 54 COR 55 ,
  • NR 54 SOR 55 NR 54 S0 2 R 57 , COOalkyl, COOaryl, CONR 54 R 55 , CONR 54 OR 55 , NR 54 R 55 ,
  • S0 2 NR 54 R 55 S-alkyl, S-alkyl, SOalkyl, S0 2 alkyl, Saryl, SOaryl, S0 2 aryl; or R 52 and R 53 may be joined to form a cyclic ring (saturated or unsaturated) from 5 to 8 atoms, optionally containing one or more heteroatoms selected from the group N, O or S.
  • R 54 , R 55 , and R 56 are independently hydrogen, alkyl, alkenyl, alkynyl, perfluoroalkyl, cycloalkyl, cycloheteroalkyl, aryl, substituted aryl, heteroaryl, substituted or hetero alkyl or the like.
  • Hetero when used to describe a compound or a group present on a compound means that one or more carbon atoms in the compound or group have been replaced by a nitrogen, oxygen, or sulfur heteroatom. Hetero may be applied to any of the hydrocarbyl groups described above such as alkyl, e.g. heteroalkyl, cycloalkyl, e.g. cycloheteroalkyl, aryl, e.g.
  • heteroaryl cycloalkenyl, cycloheteroalkenyl, and the like having from 1 to 5, and especially from 1 to 3 heteroatoms.
  • Heteroaryl refers to a monovalent heteroaromatic group derived by the removal of one hydrogen atom from a single atom of a parent heteroaromatic ring system.
  • Typical heteroaryl groups include, but are not limited to, groups derived from acridine, arsindole, carbazole, ⁇ -carboline, chromane, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole,
  • the heteroaryl group is between 5-15 membered heteroaryl, with 5-10 membered heteroaryl being particularly preferred.
  • Particular heteroaryl groups are those derived from thiophene, pyrrole, benzothiophene, benzofuran, indole, pyridine, quinoline, imidazole, oxazole and pyrazine.
  • each Y is selected from carbonyl, N, NR , O, and S; and R is independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, heteroalkyl or the like.
  • cycloheteroalkyl refers to a stable heterocyclic non- aromatic ring and fused rings containing one or more heteroatoms independently selected from N, O and S.
  • a fused heterocyclic ring system may include carbocyclic rings and need only include one heterocyclic ring.
  • heterocyclic rings include, but are not limited to, piperazinyl, homopiperazinyl, piperidinyl and morpholinyl, and are shown in the following illustrative examples:
  • each X is selected from CR , CR 2 , NR , O and S; and each Y is selected from NR , O and S; and R 58 is independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, heteroalkyl or the like.
  • cycloheteroalkyl rings may be optionally substituted with one or more groups selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, hydroxyl, keto, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioketo, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl-S(0) 2 - and aryl-S(0) 2 -.
  • Substituting groups include carbonyl or thiocarbonyl which provide, for example, lactam and urea derivatives.
  • Examples of representative cycloheteroalkenyls include the following:
  • each X is selected from CR , CR 2 , NR , O and S; and each Y is selected from carbonyl, N, NR 58 , O and S; and R 58 is independently hydrogen, alkyl, cycloalkyl,
  • cycloheteroalkyl aryl, heteroaryl, heteroalkyl or the like.
  • each X is selected from CR 2, NR , O and S; and each Y is selected from carbonyl, NR 58 , O and S; and R 58 is independently hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, heteroalkyl or the like.
  • Hetero substituent refers to a halo, O, S or N atom-containing functionality that may be present as an R 4 in a R 4 C group present as substituents directly on the ring or rings of the compounds disclosed herein, or that may be present as a substituent in any "substituted” aryl and aliphatic groups present in the compounds.
  • hetero substituents examples include:
  • each R 59 is independently an aryl or aliphatic, optionally with substitution.
  • hetero substituents containing R 59 groups preference is given to those materials having aryl and alkyl R 59 groups as defined herein. Preferred hetero substituents are those listed above.
  • Dihydroxyphosphoryl refers to the substituted or unsubstituted radical -
  • Substituted dihydroxyphosphoryl includes those groups recited in the definition of "substituted” herein, and particularly refers to a dihydroxyphosphoryl radical wherein one or both of the hydroxyl groups are substituted. Suitable substituents are described in detail below.
  • Aminohydroxyphosphoryl refers to the substituted or unsubstituted radical -
  • Substituted aminohydroxyphosphoryl includes those groups recited in the definition of "substituted” herein, and particularly refers to an aminohydroxyphosphoryl wherein the amino group is substituted with one or two substituents. Suitable substituents are described in detail below. In certain embodiments, the hydroxyl group can also be substituted.
  • Thioalkoxy refers to the substituted or unsubstituted group -SR 60 where R 60 is alkyl.
  • substituted herein, and particularly refers to a thioalkoxy group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, hydroxyl, keto, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioketo, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl-S(0) 2 - and aryl-S(0) 2 -.
  • substituents for instance from 1 to 5
  • Sulfanyl refers to the substituted or unsubstituted radical HS-.
  • Substituted sulfanyl refers to a radical such as RS- wherein R is any substituent described herein.
  • Sulfonyl refers to the divalent substituted or unsubstituted radical -S(0 2 )-.
  • Substituted sulfonyl refers to a radical such as R 61 -(0 2 )S- wherein R 61 is any substituent described herein.
  • Amino sulfonyl or “Sulfonamide” refers to the radical H 2 N(0 2 )S-
  • substituted aminosulfonyl refers to a radical such as R 62 2 N(0 2 )S- wherein each R 62 is independently any substituent described herein.
  • Sulfone refers to the substituted or unsubstituted group -S0 2 R 63 .
  • R 63 is selected from H, lower alkyl, alkyl, aryl and heteroaryl.
  • Thioaryloxy refers to the substituted or unsubstituted group -SR 64 where R 64 is aryl.
  • Thiol refers to the group -SH.
  • heterocyclic ring may have one to four heteroatoms so long as the heteroaromatic ring is chemically feasible and stable.
  • mammal refers to any member of the higher vertebrate animals comprising the class Mammalia, which includes, but is not limited to, humans.
  • melanogenesis inhibitor is used to describe a compound identified herein as possessing the ability to inhibit melanogenesis in a melanocyte.
  • an “amount effective” shall mean an amount sufficient to cover the region of skin, hair, fur, or wool surface where a change in pigmentation is desired.
  • “Pharmaceutically acceptable” means approved by a regulatory agency of the
  • Cosmetically acceptable means suitable for cosmetic applications, including topical application of the compositions disclosed herein in the absence of significant adverse side effects upon application of the composition or compounds disclosed herein.
  • Other applications include skin care applications, including but not limited to lotions, cream, cleansing creams or lotions, soaps and other cleansers, antiperspirant and/or deodorants, makeup products, such as face powders, foundations, rouge, eye shadow, mascara, eyeliner or lipstick, sun protection products, such as sunscreen or other UV-protective cosmetics, lotions or creams, hairdressing products, such as shampoo, rinses, or treatment setting agents.
  • the phrases “pharmaceutically acceptable” and “cosmeceutically acceptable” are not meant to imply mutual exclusiveness in all applications.
  • a composition may be both "pharmaceutically acceptable” and “cosmeceutically acceptable,” dependent upon the need and course of action of the compositions disclosed herein.
  • “Pharmaceutically acceptable salt” refers to a salt of a compound disclosed herein that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound.
  • Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid,
  • cyclopentanepropionic acid glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4- hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1 ,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-l-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric
  • Salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the compound contains a basic functionality, salts of non toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.
  • a "pharmaceutically acceptable salt” may also be used in conjunction with cosmeceutically-acceptable compositions.
  • pharmaceutically acceptable cation refers to a non toxic, acceptable cationic counter-ion of an acidic functional group. Such cations are exemplified by sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium cations, and the like. In some embodiments, a "pharmaceutically acceptable cation" may also be used in conjunction with cosmeceutically-acceptable compositions.
  • “Pharmaceutically acceptable vehicle” refers to a diluent, adjuvant, excipient or carrier with which a disclosed compound is administered.
  • a diluent, adjuvant, excipient or carrier with which a disclosed compound is administered.
  • a disclosed compound is administered.
  • compositions may also be used in conjunction with cosmeceutically- acceptable compositions.
  • Preventing refers to a reduction in risk of acquiring a disease or disorder (i.e., causing at least one of the clinical symptoms of the disease not to develop in a subject that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease).
  • Prodrugs refers to compounds, including derivatives of disclosed compounds, which have cleavable groups and become by solvolysis or under physiological conditions of compounds which are pharmaceutically active in vivo. Such examples include, but are not limited to, choline ester derivatives and the like, N-alkylmorpholine esters and the like.
  • Solvate refers to forms of the compound that are associated with a solvent, usually by a solvolysis reaction.
  • solvents include water, ethanol, acetic acid and the like.
  • the compounds disclosed herein may be prepared e.g. in crystalline form and may be solvated or hydrated.
  • Suitable solvates include pharmaceutically acceptable solvates, such as hydrates, and further include both stoichiometric solvates and non- stoichiometric solvates.
  • Subject includes humans.
  • the terms “human,” “patient” and “subject” are used interchangeably herein.
  • “Therapeutically effective amount” means the amount of a compound that, when administered to a subject for treating a disease, is sufficient to effect such treatment for the disease.
  • the “therapeutically effective amount” can vary depending on the compound, the disease and its severity, and the age, weight, etc., of the subject to be treated.
  • Treating” or “treatment” of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (i.e., arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g. , stabilization of a discernible symptom), physiologically, (e.g. , stabilization of a physical parameter), or both. In yet another embodiment, "treating" or
  • treatment refers to delaying the onset of the disease or disorder, or even preventing the same.
  • treating or “treatment” refers to administration of the compound or compositions disclosed herein for cosmetic purposes.
  • Prodrugs include acid derivatives such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides. Simple aliphatic or aromatic esters, amides and anhydrides derived from acidic groups pendant on the disclosed compounds are preferred prodrugs. In some cases it is desirable to prepare double ester type prodrugs such as
  • (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkylesters Preferred are the Ci to Cg alkyl, C 2 -Cg alkenyl, aryl, C 7 -Ci 2 substituted aryl, and C 7 -Ci 2 arylalkyl esters of the disclosed compounds herein.
  • isotopic variant refers to a compound that contains unnatural proportions of isotopes at one or more of the atoms that constitute such compound.
  • an “isotopic variant” of a compound can contain one or more non-radioactive isotopes, such as for example, deuterium ( 2 H or D), carbon- 13 ( 13 C), nitrogen- 15 ( 15 N), or the like.
  • non-radioactive isotopes such as for example, deuterium ( 2 H or D), carbon- 13 ( 13 C), nitrogen- 15 ( 15 N), or the like.
  • the disclosed compounds may include the preparation of isotopic variants with radioisotopes, in the instance for example, where the resulting compounds may be used for drug and/or substrate tissue distribution studies.
  • the radioactive isotopes tritium, i.e. 3 H, and carbon- 14, i.e. 14 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
  • compounds may be prepared that are substituted with positron emitting isotopes, such as U C, 18 F, 15 0 and 13 N, and would be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
  • PET Positron Emission Topography
  • enantiomers and those that are non-superimposable mirror images of each other are termed "enantiomers".
  • An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory ⁇ i.e., as (+) or (-)-isomers respectively).
  • a chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a "racemic mixture".
  • Tautomers refer to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of ⁇ electrons and an atom (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Another example of tautomerism is the aci- and nitro- forms of phenylnitromethane, that are likewise formed by treatment with acid or base.
  • Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound of interest.
  • the disclosed compounds may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)- stereoisomers or as mixtures thereof. Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art.
  • метод ⁇ ии As described herein, disclosed are embodiments relating to the identification of compounds that control melanin synthesis (melanogenesis), and the use of such compounds and compositions thereof to modify (e.g., inhibit) melanin production. Also related are methods for preventing and/or treating conditions that are causally related to aberrant melanogenesis activity, comprising (but not limited to) aberrant pigmentation, including hyperpigmentation of all etiologies, uneven pigmentation, and the like, using the compounds and compositions disclosed herein.
  • a plurality of compounds has been identified that are capable of controlling, and particularly, inhibiting melanogenesis.
  • These compounds which were not previously identified as possessing such a capability, are listed herein and referred to as novel melanogenesis modifiers.
  • the compounds and compositions disclosed herein are directed to their use in modifying pigmentation in in vitro and in vivo applications.
  • test-tube based and additional cell-based assays may be used to test the ability of modified versions and/or derivatives of compounds listed herein to alter melanogenesis.
  • In vivo applications are directed to the administration of at least one of the novel melanogenesis inhibiting compounds listed herein to a subject in need thereof to reduce pigmentation levels for prophylactic, therapeutic and/or cosmetic purposes.
  • melanogenesis inhibitors compounds that are capable of effectively and efficiently inhibiting melanogenesis (referred to herein as melanogenesis inhibitors) in mammalian cells.
  • the ability of such compounds to decrease or inhibit melanogenesis may be used to advantage to decrease the melanin content of melanocytes, which, in turn, results in decreased pigmentation or lightening of skin, hair, wool, or fur color.
  • the novel melanogenesis inhibitors disclosed herein may be topically applied to skin, hair, wool, or fur to lighten their color.
  • benzopyran compounds are disclosed that are melanogenesis modifiers, such as inhibitors, having a formula (I):
  • R 3 is selected from H, halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted aryl; and substituted or unsubstituted heteroaryl;
  • R 4 is selected from H, halo, hydroxy, alkoxy, alkenyloxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, and substituted or unsubstituted phenyl;
  • each R 5 , R 6 ' and R 8 is independently selected from H, halo, hydroxy, alkoxy, alkenyloxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, and substituted or unsubstituted phenyl;
  • R 6 and R 7 or R 7 and R 8 are joined to form a 5- or 6- membered heterocycloalkyl or heterocycloalkenyl; and the heterocycloalkyl or heterocycloalkenyl is unsubstituted or substituted with one more groups selected from alkyl, alkenyl, hydroxyalkyl, acyloxyalkyl, hydroxy, and alkoxy;
  • Another aspect of the invention provides a method for preventing inhibiting melanogenesis or a method for promoting skin lightening comprising administering an effective amount of a compound of formula I.
  • Another aspect of the invention provides a method for preventing the
  • hyperpigmentation or undesired darkening of skin comprising administering an effective amount of a compound of formula I.
  • R 7 is selected from
  • R 3 is H, CI, alkyl, or substituted or unsubstituted phenyl.
  • R 3 is H, CI,
  • R 4 is H, CI, alkyl, or substituted or unsubstituted phenyl.
  • R 4 is H, CI,
  • R 5 is H, CI, alkyl, hydroxy, or alkoxy.
  • R 5 is H, CI,
  • R 6 is H, CI, alkyl, alkenyl, hydroxy, alkoxy, or alkenyloxy.
  • R 6 is H, CI,
  • R 6 is H
  • R 8 is H, CI, alkyl, alkenyl, hydroxy, alkoxy, or alkenyloxy.
  • R 8 is H, CI,
  • R 8 is H
  • R 7 is H
  • R 4 , R 5 , R 6 is H; R 7 is as described for formula I; and R 8 is substituted or unsubstituted alkenyl. In another embodiment, R 8 is 3-methylbut-2-enyl.
  • R 8 is substituted or unsubstituted alkenyl; and R 7 is Me.
  • R 8 is 3-methylbut-2-enyl and R 7 is Me.
  • R 6 , R 7 and R 8 are as described for formula I; and R 3 is CI. [00181] In one particular embodiment of the invention, with respect to formula I, R 4 , R 5 ,
  • R 6 , and R 8 are as described for formula I; and R 3 is CI; and R 7 is H, Me, 3-methylbut-2-enyl,
  • R 7 is Me.
  • R 6 and R 7 are joined to form a 5- or 6- membered heterocycloalkyl or heterocycloalkenyl;
  • heterocycloalkyl or heterocycloalkenyl is unsubstituted or substituted with one more groups selected from alkyl, alkenyl, hydroxyalkyl, acyloxyalkyl, hydroxy, and alkoxy.
  • R 7 and R 8 are joined to form a 5- or 6- membered heterocycloalkyl or heterocycloalkenyl;
  • heterocycloalkyl or heterocycloalkenyl is unsubstituted or substituted with one more groups selected from alkyl, alkenyl, hydroxyalkyl, acyloxyalkyl, hydroxy, and alkoxy.
  • the compound is according to formulae Ila, lib, lie, or lid:
  • R 4 , R 5 , and R 6 are as described for formula I;
  • R 3 is selected from halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted phenyl;
  • R 8 is selected from H, halo, hydroxy, alkoxy, alkenyloxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted phenyl;
  • each R 6a , R 7a , R 7b , and R 8a is independently selected from H, alkyl, hydroxyalkyl, or alkenyl.
  • the compound is according to formulae Ilia, Illb, IIIc or Hid:
  • R 4 , R 5 , and R 6 are as described for formula I;
  • R 3 is selected from halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted phenyl;
  • R 8 is selected from H, halo, hydroxy, alkoxy, alkenyloxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted phenyl;
  • each R 6a , R 7a and R 7b is independently selected from H, alkyl, hydroxyalkyl, or alkenyl.
  • R 8a is H or Me.
  • R 6 is H, Me, OH, OMe, 3-methylbuten-2-yl; or 3-methylbuten-2-yloxy.
  • R 4 , and R 5 are as described for formula I;
  • R 3 is selected from halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted phenyl;
  • R 8 is selected from H, halo, hydroxy, alkoxy, alkenyloxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted phenyl;
  • each R 6a and R 7a is independently selected from H, alkyl, or alkenyl.
  • R 4 is H, CI, alkyl, hydroxy, alkoxy, or substituted or unsubstituted phenyl.
  • R 4 is H, Me
  • R 4 is H.
  • R 6a is H or
  • R a is H.
  • R a is H or Me.
  • R is H or Me.
  • R / is H or Me.
  • R 7b is Me.
  • R a is H or
  • the compound is of formula Va, or Vb: or a pharmaceutically acceptable salt, solvate or prodrug thereof, and stereoisomers, tautomers and isotopic variants thereof;
  • R 4 , R 5 , and R 6 are as in formula I;
  • R 3 is selected from halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted phenyl;
  • R 8 is selected from H, halo, hydroxy, alkoxy, alkenyloxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted phenyl.
  • R 5 is H, CI, alkyl, hydroxy, or alkoxy.
  • R 5 is H, CI,
  • R 5 is OH.
  • R 8 is H, CI, alkyl, alkenyl, hydroxy, alkoxy, or alkenyloxy.
  • R 8 is H, CI,
  • R 8 is 3- methylbut-2-enyl.
  • R 6 is H, CI, alkyl, alkenyl, hydroxy, alkoxy, or alkenyloxy.
  • R 6 is H, CI,
  • R 6 is 3- methylbut-2-enyl.
  • the compound is of formula Via, or VIb:
  • R 3 is selected from halo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted phenyl.
  • R 3 is CI, alkyl, or substituted or unsubstituted phenyl.
  • R 3 is Me, phenyl, 4-hydroxyphenyl, 3,4-dihydroxyphenyl, 4-methoxyphenyl, or 3,4-dimethoxyphenyl. In one particular embodiment, R 3 is 4-hydroxyphenyl, or 3,4-dihydroxyphenyl. In a more particular embodiment, R 3 is 4-methoxyphenyl, or 3,4-dimethoxyphenyl.
  • the compound is of formula Vila Vllb, or VIIc:
  • the compound is osajin-4'methylether, or pomiferin-3', 4 '-dimethyl ether.
  • the compound is warangalone or warangalone-4'-methylether.
  • the compound is selected from the compounds listed in Table 1.
  • the invention provides methods for inhibiting melanogenesis using the compounds of formulae I-VIIc.
  • the invention provides methods for inhibiting melanogenesis using a plant extract containing compounds of formula I.
  • the plant extract is derived from the fruit of Madura pomifera.
  • the invention provides methods for promoting skin lightening using the compounds of formulae I-VIIc.
  • the invention provides methods for promoting skin lightening using a plant extract containing compounds of formula I.
  • the plant extract is derived from the fruit of Madura pomifera.
  • a further aspect extends to a formulation that comprises a combination of a compound with respect to formulae I-VIIc, and an additional pharmaceutical or cosmetic agent.
  • the additional pharmaceutical or cosmetic agent is a like-acting agent.
  • the like acting agent is selected from a cosmetic ingredient and a pharmacologically active agent.
  • a pharmaceutical composition is prepared that is useful to treat a disease for which a melanogenesis inhibitor is indicated, which comprises a therapeutically effective amount of the combination, wherein the like acting agent is a pharmacologically active agent.
  • the like-acting agent is a skin lightening or skin bleaching compound.
  • the skin lightening or skin bleaching compound is hydroquinone, kojic acid, ascorbic acid, magnesium ascorbyl phosphate or ascorbyl glucosamine, or mixtures thereof.
  • a topical formulation is prepared that comprises a composition for cosmetic or dermatological use, which composition comprises a cosmetically and/or dermatologically effective amount of the combination stated above, wherein the like acting agent is a cosmetically active agent.
  • the like-acting agent is a skin lightening or skin bleaching compound.
  • the skin lightening or skin bleaching compound is hydroquinone, kojic acid, ascorbic acid, magnesium ascorbyl phosphate or ascorbyl glucosamine, or mixtures thereof.
  • the additional pharmaceutical or cosmetic agent is a skin care active agent.
  • the skin care active agent is an abrasive, an absorbent, an astringent, an aesthetic component, such as fragrances, pigments, colorings/colorants, essential oils, skin sensates, astringents and other aesthetic components, an antioxidant, a reducing agent, a sequestrant, a skin bleaching or lightening agent, a skin conditioning agent, for example humectants and emollients, a skin soothing agent, a skin healing agent, such as pathenol and derivatives, aloe vera, pantothenic acid, allantoin, bisbolol, dipotassium glycyrrhizinate, skin treating agents, vitamins and derivatives, such as a retinoid, or mixtures thereof.
  • the retinoid is retinol, retinal, retinol esters, retinyl propionate, retinoic acid, retinyl palmitate, or mixtures thereof.
  • the like acting agent is a pharmaceutically active agent.
  • the like-acting agent is a skin lightening or skin bleaching compound.
  • the skin lightening or skin bleaching compound is hydroquinone, kojic acid, ascorbic acid, magnesium ascorbyl phosphate or ascorbyl glucosamine, or mixtures thereof.
  • a method for altering or restoring pigmentation in mammalian skin, hair, wool or fur comprising administering to the mammalian skin, hair, wool or fur an amount of a composition comprising a pigment restoring or altering-effective amount of the combination as stated and set forth above, wherein the like acting agent is a cosmetically active agent. More particularly, the like-acting agent is a skin lightening or skin bleaching compound.
  • the skin lightening or skin bleaching compound is hydroquinone, kojic acid, ascorbic acid, magnesium ascorbyl phosphate or ascorbyl glucosamine, or mixtures thereof
  • compositions disclosed herein contemplate the use of one or more of the compounds listed herein as an active ingredient(s) for various uses.
  • the active ingredient(s) is combined with an acceptable carrier to form a topical formulation for application to the skin, for example, for cosmetic and/or therapeutic
  • Topical formulations may include ointments, lotions, pastes, creams, gels, drops, suppositories, sprays, liquids, shampoos, powders, antiperspirants, deodorants, rinses, soaps, topical make-up products, including but not limited to face power, foundation, rouge, eye shadow, mascara, eyeliner or lipstick, UV-protective products, which may include sunscreens, lotions or creams, and transdermal patches.
  • Thickeners, diluents, emulsifiers, dispersing aids or binders may be used as needed.
  • one function of the carrier is to enhance skin penetration of the active ingredient(s), and should be capable of delivering the active
  • Suitable carriers are well known to skilled practitioners, and include liposomes, ethanol, dimethylsulfoxide (DMSO), petroleum jelly (petrolatum), mineral oil (liquid petrolatum), water, dimethylformamide, dekaoxyethylene- oleylether, oleic acid, 2-pyrrolidone and Azone® brand penetration enhancer (Upjohn).
  • a particular composition may be formulated to include an active ingredient(s) as described in Table I, with one of 2-pyrrolidone, oleic acid and/or Azone® added to enhance penetration, solubilized in a base of water, ethanol, propanol and/or propylene glycol.
  • vehicles comprising liposomes may be used for topical delivery of some of the compositions disclosed herein.
  • such liposomes may be non-ionic and contain a) glycerol dilaurate (preferably in an amount of between about 5% and about 70% by weight); b) compounds having the benzopyran core found in cholesterol (preferably in an amount of between about 5% and about 45% by weight); and c) one or more fatty acid ethers having from about 12 to about 18 carbon atoms preferably in an amount of between about 5% and about 70% by weight collectively), wherein the constituent compounds of the liposomes are preferably in a ratio of about 37.5: 12.5:33.3: 16.7.
  • liposomes comprised of glycerol dilaurate/cholesterol/polyoxy ethylene -10-stearyl ether/polyoxyethylene-9-lauryl ether (GDL liposomes) are preferred.
  • Liposomes may be present in an amount, based upon the total volume of the composition, of from about 10 mg/mL to about 100 mg/mL, and more preferably from about 20 mg/mL to about 50 mg/mL. A ratio of about 37.5: 12.5:33.3: 16.7 may be used to particular advantage.
  • Suitable liposomes may be prepared in accordance with standard methods commonly used in the art.
  • composition may be prepared by combining the desired components in a suitable container and mixing them under ambient conditions in any
  • formulations may contain, for example, soybean milk or other liquid formulations derived directly from legumes or other suitable plant.
  • a formulation may, for example, contain a large proportion of soybean milk, an emulsifier that maintains the physical stability of the soybean milk, and, optionally a chelating agent, preservatives, emollients, humectants and/or thickeners or gelling agents.
  • Oil-in-water emulsions, water-in-oil emulsions, solvent-based formulations and aqueous gels known to those of skill in the art may also be utilized as vehicles for the delivery of the disclosed compositions.
  • compositions disclosed herein may also include other active ingredients, as well as inert or inactive ingredients.
  • the topically active pharmaceutical or cosmetic composition may be optionally combined with other ingredients such as moisturizers, cosmetic adjuvants, surfactants, foaming agents, conditioners, humectants, fragrances, viscosifiers, buffering agents, preservatives, sunscreens and the like.
  • Particular formulations may include at least one active ingredient (for example, a novel melanogenesis modifier described herein) or previously recognized, and particularly, like- acting agents, such as skin lighteners or skin bleachers, which may be known to those of skill in the art.
  • active ingredient for example, a novel melanogenesis modifier described herein
  • like- acting agents such as skin lighteners or skin bleachers
  • Agents known to possess similar activities and/or properties include, but are not limited to: bleaching agents; tyrosinase inhibitors; a-hydroxy acids, salts and derivatives thereof; a-keto acids, salts and derivatives thereof; ⁇ -hydroxy acids, salts and derivatives thereof; retinoids, salts and derivatives thereof; Vitamin A and related compounds; acids; phenol; methoxypropyl- gluconamide; corticosteroids; agents that block the transfer of melanosomes to keratinocytes, such as may be found in soy extracts; kojic acid; licorice extracts; and the like.
  • the retinoids include retinol, retinal, retinol esters, retinyl propionate, retinoic acid, retinyl palmitate or mixtures thereof.
  • the dose regimen will depend on a number of factors which may readily be determined, such as severity and responsiveness of the condition to be treated, but will normally be one or more doses per day, with a course of treatment lasting from several days to several months, or until a cure is effected or a diminution of disease state is achieved, or a cosmetically desired degree of melanogenesis modification (e.g., reduction in pigmentation) is achieved, depending on the application.
  • a cosmetically desired degree of melanogenesis modification e.g., reduction in pigmentation
  • concentration of a melanogenesis inhibitor of from about 0.01% to about 50%, preferably from about 0.03%> to about 10%>.
  • the compositions disclosed herein will have a concentration of melanogenesis inhibitor of from about 0.1% to about 25%, or from about 1% to about 10%>. In other embodiments, the compositions disclosed herein will have a concentration of from about 0.1% to about 75%, from about 0.5% to about 60%), from about 0.5%> to about 50%>, from about 0.5%> to about 40%>, from about 0.5%> to about 30%), from about 0.5%> to about 20%>, from about 0.5%> to about 10%>, from about 1% to about 75%o, from about 1% to about 60%>, from about 1% to about 50%, from about 1% to about 40%, from about 1% to about 30%, from about 1% to about 20%, from about 1% to about 10%, from about 5%> to about 75%, from about 5% to about 60%, from about 5% to about 50%, from about 0.1% to about 50%, from about 1% to about 40%, from about 1% to about 30%, from about 1% to about 20%, from about 1% to about 10%, from about 5%> to about 75%,
  • compositions disclosed herein will have a concentration of melanogenesis inhibitor of 0.1%, 0.5%, 0.75%,
  • compositions disclosed herein may contain from about 0.01 mg to about 100 mg of melanogenesis inhibitor, preferably about 0.1 mg to about 10 mg of melanogenesis inhibitor. In some embodiments, the compositions disclosed herein may contain from about 0.05 to about 5 mg of melanogenesis inhibitor, or from about 0.1 to about 3 mg of melanogenesis inhibitor.
  • the compositions disclosed herein may contain from about 0.1 to about 50 mg, from about 0.1 to about 45 mg, from about 0.1 to about 40 mg, from about 0.1 to about 35 mg, from about 0.1 to about 30 mg, from about 0.1 to about 25 mg, from about 0.1 to about 20 mg, from about 0.1 to about 15 mg, from about 0.1 to about 10 mg, from about 0.1 to about 5 mg, from about 0.5 to about 50 mg, from about 0.5 to about 45 mg, from about 0.5 to about 40 mg, from about 0.5 to about 35 mg, from about 0.5 to about 30 mg, from about 0.5 to about 25 mg, from about 0.5 to about 20 mg, from about 0.5 to about 15 mg, from about 0.5 to about 10 mg, from about 0.5 to about 5 mg, from about 1.0 to about 50 mg, from about 1.0 to about 45 mg, from about 1.0 to about 40 mg, from about 1.0 to about 35 mg, from about 1.0 to about 30 mg, from about 1.0 to about 25 mg, from about 1.0 to about 20 mg, from about
  • the compositions disclosed herein will contain from about 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5, mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.0 mg, 2.0 mg, 3.0 mg, 4.0 mg, 5.0 mg, 7.0 mg, 10.0 mg, 15.0 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg or 100 mg of melanogenesis inhibitor. In some embodiments, the compositions disclosed herein will contain from about 0.3 mg to about 0.75 mg of melanogenesis inhibitor.
  • compositions disclosed herein will have a concentration of melanogenesis inhibitor of from about 0.01 mg/ml to about 50 mg/ml, preferably from about 0.1 mg/ml to about 10 mg/ml. In some embodiments, the compositions disclosed herein will have a concentration of melanogenesis inhibitor of from about 0.1 mg/ml to about 5 mg/ml, or from about 0.3 mg/ml to about 3 mg/ ml.
  • the compositions will have a concentration of melanogenesis inhibitor of from about 0.1 to about 50 mg/ml, from about 0.1 to about 45 mg/ml, from about 0.1 to about 40 mg/ml, from about 0.1 to about 35 mg/ml, from about 0.1 to about 30 mg/ml, from about 0.1 to about 25 mg/ml, from about 0.1 to about 20 mg/ml, from about 0.1 to about 15 mg/ml, from about 0.1 to about 10 mg/ml, from about 0.1 to about 5 mg/ml, 0.5 to about 50 mg/ml, from about 0.5 to about 45 mg/ml, from about 0.5 to about 40 mg/ml, from about 0.5 to about 35 mg/ml, from about 0.5 to about 30 mg/ml, from about 0.5 to about 25 mg/ml, from about 0.5 to about 20 mg/ml, from about 0.5 to about 15 mg/ml, from about 0.5 to about 10 mg/ml, from about 0.5 to about 5 mg/ml, from
  • melanogenesis inhibitors or compounds that decrease or suppress melanin production and pigmentation in mammalian skin, hair, fur or wool are useful in, for example, the lightening and/or brightening of skin, hair, wool or fur for cosmetic purposes, or the treatment of hyperpigmentation or uneven pigmentation disorders such as vitiligo, ephelides, lentigines, dermal melanocytosis, cafe-au-lait spots, post-inflammatory hyperpigmentation, etc.
  • the formulation and dosing would be as described above.
  • prodrugs and derivatives of the disclosed compounds are provided.
  • Prodrugs are derivatives of the compounds which have metabolically cleavable groups and become by solvolysis or under physiological conditions the compounds which are pharmaceutically active, in vivo. Such examples include, but are not limited to, choline ester derivatives and the like, N-alkylmorpholine esters and the like.
  • Other derivatives of the compounds have activity in both their acid and acid derivative forms, but the acid sensitive form often offers advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, H., Design of
  • Prodrugs include acid derivatives well know to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides. Simple aliphatic or aromatic esters, amides and anhydrides derived from acidic groups pendant on the disclosed compounds are preferred prodrugs. In some cases it is desirable to prepare double ester type prodrugs such as (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkylesters.
  • compositions of any of the aforementioned compounds of formulae I-VIIc are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., l,l-methylene-bis-(2-hydroxy-3- naphthoate)) salts.
  • non-toxic acid addition salts i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromid
  • the compounds useful that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt.
  • the acid addition salts of the active base compounds disclosed herein are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained.
  • Those compounds useful that are acidic in nature are capable of forming base salts with various pharmaceutically acceptable cations.
  • such salts include the alkali metal and alkaline earth metal salts and, particularly, the sodium and potassium salts. These salts can be prepared by conventional techniques.
  • the chemical bases that are used as reagents to prepare the pharmaceutically acceptable base salts of the compounds disclosed herein are those that form non-toxic base salts with the acidic compounds of formulae I-VIIc.
  • Such non-toxic base salts include those derived from such pharmaceutically acceptable cations as sodium, potassium, calcium and magnesium, etc. These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired
  • pharmaceutically acceptable cations preferably under reduced pressure
  • they can also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness, as described above. In either case,
  • stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final products.
  • the compounds and their pharmaceutically acceptable salts are useful in the treatment of disorders of human pigmentation, including solar and simple lentigines (including age/liver spots), melasma/chloasma and post inflammatory hyper-pigmentation.
  • Such compounds reduce skin melanin levels by inhibiting the production of melanin, whether the latter is produced constitutively or in response to UV irradiation (such as sun exposure).
  • UV irradiation such as sun exposure
  • some of the active compounds used can be used to reduce skin melanin content in non-pathological states so as to induce a lighter skin tone, as desired by the user, or to prevent melanin accumulation in skin that has been exposed to UV irradiation.
  • They can also be used in combination with skin peeling agents (including glycolic acid or trichloroacetic acid face peels) to lighten skin tone and prevent repigmentation.
  • the appropriate dose regimen, the amount of each dose administered, and specific intervals between doses of the active compound will depend upon the particular active compound employed, the condition of the patient being treated, and the nature and severity of the disorder or condition being treated.
  • the melanogenesis inhibitor is administered in an amount and at an interval that results in the desired treatment of or improvement in the disorder or condition being treated.
  • a melanogenesis inhibitor disclosed herein can also be used in combination with sun screens (UVA or UVB blockers) to prevent repigmentation, to protect against sun or UV-induced skin darkening or to enhance their ability to reduce skin melanin and their skin bleaching action.
  • sun screens UVA or UVB blockers
  • a melanogenesis inhibitor can also be used in combination with retinoic acid or its derivatives or any compounds that interact with retinoic acid receptors and accelerate or enhance the ability to reduce skin melanin and skin bleaching action, or enhance the ability to prevent the accumulation of skin melanin.
  • a melanogenesis inhibitor can also be used in combination with 4-hydroxyanisole.
  • the melanogenesis inhibitor can also be used in combination with ascorbic acid, its derivatives and ascorbic-acid based products (such as magnesium ascorbate) or other products with an anti-oxidant mechanism (such as resveratrol or vitamin A or retinoic acid) which accelerate or enhance their ability to reduce skin melanin and their skin bleaching action.
  • ascorbic acid its derivatives and ascorbic-acid based products (such as magnesium ascorbate) or other products with an anti-oxidant mechanism (such as resveratrol or vitamin A or retinoic acid) which accelerate or enhance their ability to reduce skin melanin and their skin bleaching action.
  • the melanogenesis inhibitor is a benzopyran melanogenesis inhibitor as in Formula I.
  • the melanogenesis inhibitor is an osajin derivative, such as osajin-4' -methyl ether.
  • the melanogenesis inhibitor is pomiferin-3', 4 '-dimethyl ether or a pomiferin-3', 4 '-dimethyl ether derivative.
  • the plant extract is derived from a plant of the Osage family. In some
  • the plant extract is derived from the fruit of Madura pomifera or its extract.
  • the plant species listed are not meant to be limiting as to the source of the melanogenesis inhibitor.
  • Other plant species from which plant extracts can be prepared comprising a melanogenesis inhibitor, including an osajin derivative, such as osajin-4'-methyl ether or pomiferin-3 ',4'- dimethyl ether or a pomiferin-3 ',4 '-dimethyl ether derivative, may also be used in conjunction with the disclosure herein.
  • the plant extract is substantially purified or partially purified for concentration of the melanogenesis inhibitor.
  • the plant extract may be substantially liquefied or partially liquefied for administration to a patient in need thereof.
  • the plant extract may also be processed to remove particulate matter prior to administration.
  • the plant extract contains about 0.1 to about 90%, about 0.5% to about 80%, about 1% to about 75%, about 5% to about 60%, about 10% to about 50%, about 25% to about 40% melanogenesis inhibitor.
  • the plant extract contains about 1% to about 80%>, about 1% to about 70%>, about 1% to about 60%>, about 1% to about 50%, about 1% to about 40%, about 1% to about 30%, about 1% to about 20%, about 1% to about 10%), about 5% to about 80%, about 5% to about 70%, about 5% to about 60%, about
  • the plant extract contains about
  • a plant extract is provided containing an osajin derivative, such as osajin-4 '-methyl ether for use as an inhibitor of melanogenesis.
  • a plant extract is provided containing pomiferin-3', 4 '-dimethyl ether or a pomiferin-3', 4 '-dimethyl ether derivative.
  • formulations of a plant extract containing pomiferin-3 ',4 '-dimethyl ether or a pomiferin-3 ',4 '-dimethyl ether derivative are also provided.
  • methods for preventing, treating, ameliorating or managing a disease or condition involving undesired or aberrant melanogenesis which comprises administering to a patient in need thereof or desirous of such prevention, treatment, amelioration, or management, a prophylactically, therapeutically or cosmetically effective melanogenesis-inhibiting amount of a plant extract containing an osajin derivative, such as osajin-4 '-methyl ether, or pomiferin-3 ',4 '-dimethyl ether or a pomiferin-3 ',4'- dimethyl ether derivative .
  • an osajin derivative such as osajin-4 '-methyl ether
  • provided are methods for altering or restoring pigmentation in mammalian skin, hair, wool, or fur comprising administering to a mammalian skin, hair, wool or fur an effective amount of a plant extract containing an osajin derivative, such as osajin-4 '-methyl ether or pomiferin-3 ',4 '-dimethyl ether, or a pomiferin-3 ',4 '-dimethyl ether derivative.
  • an osajin derivative such as osajin-4 '-methyl ether or pomiferin-3 ',4 '-dimethyl ether, or a pomiferin-3 ',4 '-dimethyl ether derivative.
  • osajin derivative such as osajin-4 '-methyl ether or pomiferin-3 ',4 '-dimethyl ether, or a pomiferin-3 ',4 '-dimethyl ether derivative.
  • osajin derivative such as o
  • Madura pomifera fruit extract can be prepared from Madura pomifera fruit powder.
  • the plant extract 5 grams of Maclura pomifera fruit powder is suspended in 25 ml of 200 proof ethanol, and incubated overnight at room temperature on an agitator. The mixture is then centrifuged twice at 1000 rpm for 10 min in a swing rotor, and then an additional 5 min as above. The supernatant is then filtered through Whatman Grade 1 (11 micron) filter paper. The clarified fluid is then further allowed to settle for an hour, and the supernatant is removed and used as the ethanolic extract of the fruit of Madura pomifera.
  • Extract derived from the fruit of Maclura pomifera may contain a potent inhibitor of melanin synthesis in cultured melanocytes and may be an effective depigmenting agent in human skin tissues.
  • the plant extract compositions disclosed herein will comprise plant extract of from about 1% to about 75%, preferably from about 5% to about 50%, more preferably from about 10% to about 30%, and more preferably about 20%.
  • the compositions disclosed herein will have an amount of plant extract of from about 5% to about 35%, or from about 15% to about 25%.
  • compositions disclosed herein will have an amount of plant extract of from about 5% to about 75%), from about 5% to about 70%>, from about 5% to about 65%, from about 5% to about 60%, from about 5% to about 55%, from about 5% to about 50%, from about 5% to about 45%, from about 5%) to about 40%, from about 5% to about 35%, from about 5% to about 30%, from about 5%) to about 25%o, from about 5% to about 20%, from about 5% to about 15%, from about 5% to about 10%), from about 10% to about 75%, from about 10% to about 70%, from about 10% to about 65%), from about 10% to about 60%, from about 10% to about 55%, from about 10% to about 50%), from about 10% to about 45%, from about 10% to about 40%, from about 10% to about 35%), from about 10% to about 30%, from about 10% to about 25%, from about 10% to about 20%, and from about 10% to about 15%.
  • compositions disclosed herein will have an amount of plant extract of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 32%, 34%, 35%, 36%, 38%, 40%, 45%, 50%, 55%, 60%, 65%, 70%) or 75%).
  • the amount of plant extract included in the disclosed compositions will depend on a number of factors, including the amount of melanogenesis inhibitor, including an osajin derivative, such as osajin-4 '-methyl ether, or pomiferin-3', 4 '-dimethyl ether or a pomiferin-3',4'- dimethyl ether derivative, contained in the plant extract preparation. Testing of the plant extract preparations to determine the amount of melanogenesis inhibitor included in each preparation is contemplated within the scope of the embodiments described herein.
  • melanogenesis inhibitor including an osajin derivative, such as osajin-4 '-methyl ether, or pomiferin-3', 4 '-dimethyl ether or a pomiferin-3',4'- dimethyl ether derivative
  • compositions disclosed herein may contain from about 10 mg to about 100 g of plant extract per 100 ml of composition, preferably about 1 g to about 50 g of plant extract per 100 ml of composition. In some embodiments, the compositions disclosed herein may contain from about 100 mg to about 50 g of plant extract per 100 ml of composition, or from about 1 g to about 20 g of plant extract per 100 ml of composition.
  • the compositions disclosed herein may contain from about 100 mg to about 50 g, from about 100 mg to about 45 g, from about 100 mg to about 40 g, from about 100 mg to about 35 g, from about 100 mg to about 30 g, from about 100 mg to about 25 g, from about 100 mg to about 20 g, from about 100 mg to about 15 g, from about 100 mg to about 10 g, from about 100 mg to about 5 g, from about 100 mg to about 1 g, 1 g to about 50 g, from about 1 g to about 45 g, from about 1 g to about 40 g, from about 1 g to about 35 g, from about 1 g to about 30 g, from about 1 g to about 25 g, from about 1 g to about 20 g, from about 1 g to about 15 g, from about 1 g to about 10 g, from about 1 g to about 5 g, from about 2.5 g to about 50 g, from about 2.5 g to about 45 g, from about
  • compositions disclosed herein will contain from about 0.5 g, 1 g, 2 g, 3 g, 4 g, 5 g, 6 g, 7 g, 8 g, 9 g, 10 g, 11 g, 12 g, 13 g, 14 g, 15 g, 16 g,
  • a plant extract containing an osajin derivative such as osajin-4' -methyl ether, or pomiferin-3', 4 '-dimethyl ether or a pomiferin-3', 4 '-dimethyl ether derivative and a like-acting agent.
  • an osajin derivative such as osajin-4' -methyl ether, or pomiferin-3', 4 '-dimethyl ether or a pomiferin-3', 4 '-dimethyl ether derivative
  • a like-acting agent can be any cosmetic ingredient or a pharmacologically active agent disclosed herein.
  • compositions useful in treating disease for which a melanogenesis inhibitor is indicated comprising a therapeutically effective amount of a plant extract containing an osajin derivative, such as osajin-4 '-methyl ether, or pomiferin-3 ',4 '-dimethyl ether or a pomiferin-3 ',4'- dimethyl ether derivative in combination with a like-acting agent.
  • an osajin derivative such as osajin-4 '-methyl ether, or pomiferin-3 ',4 '-dimethyl ether or a pomiferin-3 ',4'- dimethyl ether derivative in combination with a like-acting agent.
  • the pharmaceutical composition comprising a plant extract containing an osajin derivative, such as osajin-4 '-methyl ether, or pomiferin-3 ',4 '-dimethyl ether or a pomiferin-3 ',4 '-dimethyl ether derivative in combination with a like-acting agent is a topical formulation for cosmetic or dermatological use.
  • an osajin derivative such as osajin-4 '-methyl ether, or pomiferin-3 ',4 '-dimethyl ether or a pomiferin-3 ',4 '-dimethyl ether derivative in combination with a like-acting agent.
  • methods for preventing, treating, ameliorating or managing a disease or condition involving undesired or aberrant melanogenesis, which comprises administering to a patient in need thereof or desirous of such prevention, treatment, amelioration or management, a pharmaceutical or cosmetic composition comprising prophylactically, therapeutically or cosmetically effective melanogenesis-inhibiting amount of a combination of a plant extract containing an osajin derivative, such as osajin-4 '-methyl ether, or pomiferin-3 ',4 '-dimethyl ether or a pomiferin-3 ',4 '-dimethyl ether derivative with a like-acting agent.
  • an osajin derivative such as osajin-4 '-methyl ether
  • pomiferin-3 ',4 '-dimethyl ether or a pomiferin-3 ',4 '-dimethyl ether derivative with a like-acting agent.
  • pigmentation in mammalian skin, hair, wool or fur comprising administering to a mammalian skin, hair, wool or fur an amount of a composition comprising a pigment-restoring or altering- effective amount of a combination of a plant extract containing an osajin derivative, such as osajin-4' -methyl ether, or pomiferin-3', 4 '-dimethyl ether or a pomiferin-3', 4 '-dimethyl ether derivative with a like-acting agent.
  • the like-acting agent is a skin lightening compound.
  • the compounds disclosed herein can be used to treat animals or, preferably, humans that have diseases, conditions, or disorders caused by the production or overproduction of melanin.
  • diseases, conditions, or disorders include those that can be characterized by discolorations of the skin or hair such as, for example, hyperpigmentation caused by inflammation or from diseases such as melasma, or brown spots such as "cafe au lait" macules.
  • a subject may wish to lighten the color of his or her hair or skin.
  • treatment shall refer to any and all uses of the disclosed compositions which remedy a disease state, one or more symptoms or one or more effects, or otherwise prevent, hinder, retard, or reverse the progression of disease or one or more other undesirable symptoms or effects in any way whatsoever.
  • lowering refers, in a first instance, to a decrease of at least about 10%, in a further instance, to a decrease of at least about 25%, and in a still further instance, to a decrease of at least about 50%, in the amount of melanin synthesized de novo.
  • the compounds used in the methods disclosed herein may be used alone or in combination with each other.
  • the methods also include the additional use of other compounds known in the art to affect melanin synthesis such as tyrosinase inhibitors.
  • tyrosinase inhibitors are known to those skilled in the art and include various derivatives of resorcinol, hydroquinone, kojic acid, melamine, and various types of plant extracts, among others.
  • the disclosure relates both to methods of modifying, and particularly inhibiting the pigmentation of skin in which the active compound used, or a pharmaceutically acceptable salt thereof, and one or more of the other active ingredients referred to above are administered together, as part of the same pharmaceutical composition, as well as methods in which they are administered separately as part of an appropriate dose regimen designed to obtain the benefits of the combination therapy.
  • the appropriate dose regimen, the amount of each dose administered, and specific intervals between doses of each active agent will depend upon the specific combination of active agents employed, the condition of the patient being treated, and the nature and severity of the disorder or condition being treated.
  • Such additional active ingredients will generally be administered in amounts less than or equal to those for which they are effective as single topical therapeutic agents.
  • the FDA approved dosages for such active agents that have received FDA approval for administration to humans are publicly available.
  • any of the compounds used according to a skin-lightening method disclosed herein may be used in combination with a tyrosinase inhibitor or other skin- whitening agent as currently known in the art or to be developed in the future, including any one or more of those agents described in the following patent publications: U.S. Patent No. 4,278,656 to Nagai et al, issued Jul. 14, 1981; U.S. Patent No. 4,369,174 to Nagai et al, issued Jan. 18, 1983; U.S. Patent No. 4,959,393 to Torihara et al, issued Sep. 25, 1990; U.S. Patent No. 5,580,549 to Fukuda et al, issued Dec.
  • JP 7242687 by Shiseido Co. Ltd. published Sep. 19, 1995; JP 7324023 by Itogawa H, published Dec. 12, 1995; JP 8012552 by Shiseido Co. Ltd., published Jan. 16, 1996; JP 8012554 by Shiseido Co. Ltd., published Jan. 16, 1996; JP 8012557 by Shiseido Co. Ltd., published Jan. 16, 1996; JP 8012560 by Shiseido Co. Ltd., published Jan. 16, 1996; JP 8012561 by Shiseido Co. Ltd., published Jan. 16, 1996; JP 8134090 by Fujisawa, published May 28,1996; JP 8168378 by Kirinjo KK, published Jul.
  • JP 8277225 by Kansai Koso K published Oct. 22, 1996; JP 9002967 by Sanki Shoji KK, published Jan. 7, 1997; JP 9295927 by Yagi Akira, published Nov. 18, 1997; JP 10072330 by Kansai Kouso, published Mar. 17, 1998; JP 10081626 by Kamiyama KK, published Mar. 31, 1998; JP 10101543 by Kansai Kouso KK, published Apr. 21, 1998; JP 11071231 by Maruzen Pharm., published Mar. 16, 1999; JP
  • reducing skin pigmentation is meant a detectable decrease in the amount of melanin in the skin, preferably causing a lightening of the skin as a result of a lowering of the amount of melanin synthesized de novo.
  • the term "lowering" as presently used refers, in a first instance, to a decrease of at least about 10%, in a further instance, to a decrease of at least about 25%, and in a still further instance, to a decrease of at least about 50%, in the amount of melanin synthesized de novo.
  • This lowering of melanin synthesized de novo is preferably visually distinguishable to the naked eye, i.e., would not require the aid of a microscope or other such means to detect its occurrence.
  • compositions comprising an effective amount of such a compound in a pharmaceutically acceptable carrier, can be administered to a patient, person, or animal having a disease, disorder, or condition which is of a type that produces, or overproduces, melanin.
  • the amount of compound which will be effective in the treatment of a particular disease, disorder, or condition will depend on the nature of the disease, disorder, or condition, and can be determined by standard clinical techniques. Where possible, it is desirable to determine in vitro the cytotoxicity of the compound to the tissue type to be treated, and then in a useful animal model system prior to testing and use in humans.
  • the compound can be administered for the reduction or increase of melanin synthesis by any means that results in contact of the active agent with its site of action in the body of a mammal.
  • the compounds can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. Each can be administered alone, but is preferably
  • compositions can be adapted for oral, parenteral, rectal, and preferably topical, administration, and can be in unit dosage form, in a manner well known to those skilled in the pharmaceutical art.
  • Parenteral administration includes but is not limited to, injection subcutaneously, intravenously, intraperitoneally or intramuscularly. However, topical application is preferred.
  • Cosmetic applications for methods disclosed herein include the topical application of compositions containing one or more compounds to enhance or otherwise alter the visual appearance of skin or hair. Occurrences in the skin or hair of noticeable but undesired pigmentation as a result of melanin production, overproduction or underproduction can be treated using the methods disclosed herein.
  • the compounds and compositions can be used to achieve improvements in skin or hair appearance, as by brightening the same, adding or enhancing luster, and the like. Suitable formulations for these purposes can be prepared by those skilled in the art, and such details of preparation are considered within the scope.
  • compositions may be applied to both a “pharmaceutical application” and a “cosmetic application” dependent upon the need and course of action called for.
  • An effective dosage and treatment protocol can be determined by conventional means, starting with a low dose in laboratory animals and then increasing the dosage while monitoring the effects, and systematically varying the dosage regimen as well.
  • Animal studies preferably mammalian studies, are commonly used to determine the maximal tolerable dose, or MTD, of a bioactive agent per kilogram weight. Those skilled in the art can extrapolate doses for efficacy and avoidance of toxicity to other species, including humans.
  • the endpoint chosen in a particular case will vary according to the disease, condition, or disorder being treated, the outcome desired by the patient, subject, or treating physician, and other factors.
  • the composition is being used for cosmetic purposes, such as to lighten skin color such as, for example, to reverse hyperpigmentation caused by, for example, inflammation or diseases such as melasma, or to modify hair color
  • any one of a number of endpoints can be chosen.
  • endpoints can be defined subjectively such as, for example, when the subject is simply "satisfied" with the results of the treatment.
  • the endpoint can be determined by the patient's, or the treating physicians, satisfaction with the results of the treatment.
  • endpoints can be defined objectively.
  • the patient's or subject's skin or hair in the treated area can be compared to a color chart. Treatment is terminated when the color of the skin or hair in the treated area is similar in appearance to a color on the chart.
  • the reflectance of the treated skin or hair can be measured, and treatment can be terminated when the treated skin or hair attains a specified reflectance.
  • the melanin content of the treated hair or skin can be measured.
  • Treatment can be terminated when the melanin content of the treated hair or skin reaches a specified value.
  • Melanin content can be determined in any way known to the art, including by histological methods, with or without enhancement by stains for melanin.
  • the disclosed compounds can be administered topically, e.g., as patches, ointments, creams, gels, lotions, solutions, foams, masks or transdermal administration.
  • the compounds can also be administered orally in solid or semi-solid dosage forms, such as hard or soft-gelatin capsules, tablets, or powders, or in liquid dosage forms, such as elixirs, syrups, or suspensions. Additionally, the compounds can also be administered parenterally, in sterile liquid dosage forms or in suppository form.
  • the composition is preferably of high purity and substantially free of potentially harmful contaminants, e.g., at least National Food (NF) grade, generally at least analytical grade, and preferably at least pharmaceutical grade.
  • NF National Food
  • synthesis or subsequent purification shall preferably result in a product that is substantially free of any potentially contaminating toxic agents that may have been used during the synthesis or purification procedures.
  • compositions can be applied directly to the skin.
  • the active ingredient can be formulated in a solution, gel, lotion, ointment, cream, suspension, foam, mask, paste, liniment, powder, tincture, aerosol, patch, or the like in a pharmaceutically or cosmetically acceptable form by methods well known in the art.
  • the composition can be any of a variety of forms common in the pharmaceutical or cosmetic arts for topical application to animals or humans, including solutions, lotions, sprays, creams, ointments, salves, gels, etc., as described below.
  • Preferred agents are those that are viscous enough to remain on the treated area, those that do not readily evaporate, and/or those that are easily removed by rinsing with water, optionally with the aid of soaps, cleansers and/or shampoos.
  • Actual methods for preparing topical formulations are known or apparent to those skilled in the art, and are described in detail in
  • one or more of a number of agents can be added in the topical formulations including, but not limited to, dimethylsulfoxide, dimethylacetamide, dimethylformamide, surfactants, azone, alcohol, acetone, propylene glycol and polyethylene glycol.
  • agents can be added in the topical formulations including, but not limited to, dimethylsulfoxide, dimethylacetamide, dimethylformamide, surfactants, azone, alcohol, acetone, propylene glycol and polyethylene glycol.
  • physical methods can also be used to enhance transdermal penetration such as, e.g., by iontophoresis or sonophoresis.
  • liposomes may be employed.
  • a topically applied composition contains a pharmaceutically effective amount of at least one of the disclosed compounds as described herein, and those ingredients as are necessary for use as a carrier, such as an emulsion, a cream, an ointment, an ophthalmic ointment, an aqueous solution, a lotion or an aerosol.
  • a carrier such as an emulsion, a cream, an ointment, an ophthalmic ointment, an aqueous solution, a lotion or an aerosol.
  • Non-limiting examples of such carriers are described in more detail below and may be found in International Patent Publication WO
  • the pharmaceutical compositions may also include optional components.
  • optional components should be suitable for application to keratinous tissue, that is, when incorporated into the composition, they are suitable for use in contact with human keratinous tissue without undue toxicity, incompatibility, instability, allergic response, and the like within the scope of sound medical judgment.
  • optional components are useful provided that they do not unacceptably alter the benefits of the active compounds disclosed herein.
  • CTFA Cosmetic Ingredient Handbook, Second Edition (1992) describes a wide variety of non- limiting cosmetic and pharmaceutical ingredients commonly used in the skin care industry, which are suitable for use in the compositions disclosed herein.
  • abrasives examples include: abrasives, absorbents, aesthetic components such as fragrances, pigments, colorings/colorants, essential oils, skin sensates, astringents, etc. (e.g., clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate), anti-acne agents, anti- caking agents, antifoaming agents, antimicrobial agents (e.g., iodopropyl butylcarbamate), antioxidants, binders, biological additives, buffering agents, bulking agents, chelating agents, chemical additives, colorants, cosmetic astringents, cosmetic biocides, denaturants, drug astringents, external analgesics, film formers or materials, e.g., polymers, for aiding the film- forming properties and substantivity of the composition (e.g., copolymer of eicosene and vinyl pyrrol
  • the topical compositions also comprise a dermatologically acceptable carrier.
  • dermatologically acceptable carrier means that the carrier is suitable for topical application to the skin, i.e., keratinous tissue, has good aesthetic properties, is compatible with the active agents disclosed herein and any other components, and will not cause any safety or toxicity concerns.
  • a safe and effective amount of carrier is from about 10% to about 99.99%, preferably from about 30%> to about 99.9%, more preferably from about 50%> to about 98%>, and most preferably from about 60% to about 95% of the composition.
  • the carrier utilized in the disclosed compositions can be in a wide variety of forms. These include emulsion carriers, including, but not limited to, oil-in-water, water-in-oil, water-in-oil-in-water, and oil-in-water-in-silicone emulsions, a cream, an ointment, an ophthalmic ointment, an aqueous solution, a lotion or an aerosol. As will be understood by the skilled artisan, a given component will distribute primarily into either the water or oil/silicone phase, depending on the water solubility/dispersibility of the component in the composition.
  • emulsion carriers including, but not limited to, oil-in-water, water-in-oil, water-in-oil-in-water, and oil-in-water-in-silicone emulsions, a cream, an ointment, an ophthalmic ointment, an aqueous solution, a lotion or an aerosol.
  • Emulsions generally contain a pharmaceutically effective amount of an agent disclosed herein and a lipid or oil.
  • Lipids and oils may be derived from animals, plants, or petroleum and may be natural or synthetic (i.e., man-made).
  • Preferred emulsions also contain a humectant, such as glycerin.
  • Emulsions will preferably further contain from about 1% to about 10%), more preferably from about 2% to about 5%, of an emulsifier, based on the weight of the carrier.
  • Emulsifiers may be nonionic, anionic or cationic. Suitable emulsifiers are described in, for example, U.S. Patent No. 3,755,560, issued to Dickert, et al. Aug. 28, 1973; U.S. Patent No. 4,421,769, issued to Dixon, et al. Dec. 20, 1983; and McCutcheon's Detergents and Emulsifiers, North American Edition, pages 317-324
  • the emulsion may also contain an anti-foaming agent to minimize foaming upon application to the keratinous tissue.
  • Anti-foaming agents include high molecular weight silicones and other materials well known in the art for such use.
  • Suitable emulsions may have a wide range of viscosities, depending on the desired product form. Exemplary low viscosity emulsions, which are preferred, have a viscosity of about
  • the emulsion may also contain an anti-foaming agent to minimize foaming upon application to the keratinous tissue.
  • Anti-foaming agents include high molecular weight silicones and other materials well known in the art for such use.
  • One type of emulsion is a water-in-silicone emulsion.
  • Water-in-silicone emulsions contain a continuous silicone phase and a dispersed aqueous phase.
  • Preferred water-in-silicone emulsions as disclosed herein comprise from about 1% to about 60%, preferably from about 5% to about 40%), more preferably from about 10%> to about 20%>, by weight of a continuous silicone phase.
  • the continuous silicone phase exists as an external phase that contains or surrounds the discontinuous aqueous phase described hereinafter.
  • the continuous silicone phase may contain a polyorganosiloxane oil.
  • a preferred water-in-silicone emulsion system is formulated to provide an oxidatively stable vehicle for delivery of a pharmaceutically effective amount of an agent disclosed herein.
  • the continuous silicone phase of these preferred emulsions comprises between about 50%> and about 99.9% by weight of organopolysiloxane oil and less than about 50% by weight of a non-silicone oil.
  • the continuous silicone phase comprises at least about 50%, preferably from about 60% to about 99.9%, more preferably from about 70% to about 99.9%, and even more preferably from about 80% to about 99.9%, polyorganosiloxane oil by weight of the continuous silicone phase, and up to about 50% non-silicone oils, preferably less about 40%, more preferably less than about 30%, even more preferably less than about 10%, and most preferably less than about 2%, by weight of the continuous silicone phase.
  • These useful emulsion systems may provide more oxidative stability over extended periods of time than comparable water-in-oil emulsions containing lower concentrations of the polyorganosiloxane oil.
  • the organopolysiloxane oil for use in the composition may be volatile, nonvolatile, or a mixture of volatile and non-volatile silicones.
  • nonvolatile refers to those silicones that are liquid under ambient conditions and have a flash point (under one atmospheric of pressure) of or greater than about 100° C.
  • volatile refers to all other silicone oils.
  • Suitable organopolysiloxanes can be selected from a wide variety of silicones spanning a broad range of volatilities and viscosities. Examples of suitable organopolysiloxane oils include polyalkylsiloxanes, cyclic polyalkylsiloxanes, and polyalkylarylsiloxanes, which are known to those skilled in the art and commercially available.
  • the continuous silicone phase may contain one or more non-silicone oils.
  • non-silicone oils in the continuous silicone phase are preferably minimized or avoided altogether so as to further enhance oxidative stability of the pharmaceutically effective agent in the compositions.
  • Suitable non-silicone oils have a melting point of about 25°C or less under about one atmosphere of pressure.
  • non-silicone oils suitable for use in the continuous silicone phase are those well known in the chemical arts in topical personal care products in the form of water-in-oil emulsions, e.g. mineral oil, vegetable oils, synthetic oils, semisynthetic oils, etc.
  • Useful topical compositions comprise from about 30% to about 90%>, more preferably from about 50% to about 85%, and most preferably from about 70% to about 80% of a dispersed aqueous phase.
  • the term "dispersed phase” is a term well- known to one skilled in the art which means that the phase exists as small particles or droplets that are suspended in and surrounded by a continuous phase.
  • the dispersed phase is also known as the internal or discontinuous phase.
  • the dispersed aqueous phase is a dispersion of small aqueous particles or droplets suspended in and surrounded by the continuous silicone phase described hereinbefore.
  • the aqueous phase can be water, or a combination of water and one or more water soluble or dispersible ingredients.
  • Nonlimiting examples of such optional ingredients include thickeners, acids, bases, salts, chelants, gums, water-soluble or dispersible alcohols and polyols, buffers, preservatives, sunscreening agents, colorings, and the like.
  • Topical compositions typically comprise from about 25% to about 90%>, preferably from about 40% to about 80%, more preferably from about 60% to about 80%, water in the dispersed aqueous phase by weight of the composition.
  • the water-in-silicone emulsions preferably comprise an emulsifier.
  • the composition contains from about 0.1% to about 10% emulsifier, more preferably from about 0.5%> to about 7.5%, most preferably from about 1% to about 5%, emulsifier by weight of the composition.
  • the emulsifier helps disperse and suspend the aqueous phase within the continuous silicone phase.
  • emulsifying agents can be employed herein to form the preferred water-in-silicone emulsion.
  • Known or conventional emulsifying agents can be used in the composition, provided that the selected emulsifying agent is chemically and physically compatible with essential components of the composition, and provides the desired dispersion characteristics.
  • Suitable emulsifiers include silicone emulsifiers, e.g., organically modified organopolysiloxanes, also known to those skilled in the art as silicone surfactants, non-silicon- containing emulsifiers, and mixtures thereof, known by those skilled in the art for use in topical personal care products.
  • Useful emulsifiers include a wide variety of silicone emulsifiers. These silicone emulsifiers are typically organically modified organopolysiloxanes, also known to those skilled in the art as silicone surfactants. Suitable emulsifiers are described, for example, in
  • Other preferred topical carriers include oil-in-water emulsions, having a continuous aqueous phase and a hydrophobic, water-insoluble phase ("oil phase") dispersed therein.
  • oil phase hydrophobic, water-insoluble phase
  • suitable carriers comprising oil-in-water emulsions are described in U.S. Patent No. 5,073,371 to Turner, D. J. et al, issued Dec. 17, 1991, and U.S. Patent No. 5,073,372, to Turner, D. J. et al, issued Dec. 17, 1991.
  • An especially preferred oil-in-water emulsion, containing a structuring agent, hydrophilic surfactant and water, is described in detail hereinafter.
  • a preferred oil-in-water emulsion comprises a structuring agent to assist in the formation of a liquid crystalline gel network structure. Without being limited by theory, it is believed that the structuring agent assists in providing rheological characteristics to the composition which contribute to the stability of the composition.
  • the structuring agent may also function as an emulsifier or surfactant.
  • Preferred compositions comprise from about 0.5% to about 20%, more preferably from about 1% to about 10%, most preferably from about 1% to about 5%, by weight of the composition, of a structuring agent.
  • the preferred structuring agents are selected from the group consisting of stearic acid, palmitic acid, stearyl alcohol, cetyl alcohol, behenyl alcohol, stearic; acid, palmitic acid, the polyethylene glycol ether of stearyl alcohol having an average of about 1 to about 21 ethylene oxide units, the polyethylene glycol ether of cetyl alcohol having an average of about 1 to about 5 ethylene oxide units, and mixtures thereof.
  • the preferred oil-in-water emulsions comprise from about 0.05%> to about 10%>, preferably from about 1% to about 6%, and more preferably from about 1% to about 3% of at least one hydrophilic surfactant which can disperse the hydrophobic materials in the water phase (percentages by weight of the topical carrier).
  • the surfactant at a minimum, must be hydrophilic enough to disperse in water.
  • Suitable surfactants include any of a wide variety of known cationic, anionic, zwitterionic, and amphoteric surfactants. See, McCutcheon's. Detergents and
  • Emulsifiers North American Edition (1986), published by Allured Publishing Corporation; U.S. Patent No. 5,011,681 to Ciotti et al, issued Apr. 30, 1991; U.S. Patent No. 4,421,769 to Dixon et al. issued Dec. 20, 1983; and U.S. Patent No. 3,755,560.
  • the exact surfactant chosen depends upon the pH of the composition and the other components present.
  • Preferred are cationic surfactants, especially dialkyl quaternary ammonium compounds, examples of which are described in U.S. Patent No. 5,151,209 to McCall et al. issued Sep. 29, 1992; U.S. Patent No. 5,151,210 to Steuri et al. issued Sep. 29, 1992; U.S. Patent Nos. 5,120,532; U.S. Patent No.
  • cationic emulsifiers include amino-amides.
  • Nonlimiting examples of these cationic emulsifiers include stearamidopropyl PG-dimonium chloride phosphate, behenamidopropyl PG dimonium chloride, stearamidopropyl ethyldimonium ethosulfate, stearamidopropyl dimethyl (myristyl acetate) ammonium chloride, stearamidopropyl dimethyl cetearyl ammonium tosylate, stearamidopropyl dimethyl ammonium chloride, stearamidopropyl dimethyl ammonium lactate, and mixtures thereof.
  • anionic surfactants are also useful herein. See, e.g., U.S. Patent
  • the preferred oil-in-water emulsion comprises from about 25% to about 98%>, preferably from about 65% to about 95%, more preferably from about 70% to about 90% water by weight of the topical carrier.
  • the hydrophobic phase is dispersed in the continuous aqueous phase.
  • the hydrophobic phase may contain water insoluble or partially soluble materials such as are known in the art, including but not limited to the silicones described herein in reference to silicone-in- water emulsions, and other oils and lipids such as described above in reference to emulsions.
  • compositions disclosed herein may comprise a dermatologically acceptable emollient.
  • emollient refers to a material useful for the prevention or relief of dryness, as well as for the protection of the skin.
  • suitable emollients are known and may be used herein. See, e.g., Sagarin,
  • Lotions and creams according to the embodiments disclosed herein generally comprise a solution carrier system and one or more emollients.
  • Lotions typically comprise from about 1% to about 20%, preferably from about 5% to about 10% of emollient; from about 50% to about 90%, preferably from about 60% to about 80% water; and a pharmaceutically effective amount of an agent described herein.
  • a cream typically comprises from about 5% to about 50%, preferably from about 10% to about 20% of emollient; from about 45% to about 85%, preferably from about 50% to about 75% water; and a pharmaceutically effective amount of an agent described herein.
  • Ointments may comprise a simple carrier base of animal or vegetable oils or semisolid hydrocarbons (oleaginous); absorption ointment bases which absorb water to form emulsions; or water soluble carriers, e.g., a water soluble solution carrier.
  • Ointments may further comprise a thickening agent, such as described in Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1, pp. 72-73 (1972), incorporated herein by reference, and/or an emollient.
  • an ointment may comprise from about 2% to about 10% of an emollient; from about 0.1% to about 2% of a thickening agent; and a pharmaceutically effective amount of an agent described herein.
  • 1000 g of topical cream is prepared from the following types and amounts of ingredients: a pharmaceutically effective amount of an agent disclosed herein, tegacid regular (150 g) (a self-emulsifying glyceryl monostearate from
  • the methylparaben mixture is added slowly to the tegacid and spermaceti melt, with constant stirring. The addition is continued for at least 30 minutes with additional stirring until the temperature has dropped to 40-45°C. Finally, sufficient water is added to bring the final weight to 1000 g and the preparation stirred to maintain homogeneity until cooled and congealed.
  • 1000 g of a topical ointment is prepared from the following types and amounts of ingredients: a pharmaceutically effective amount of an agent disclosed herein, zinc oxide (50 g), calamine (50 g), liquid petrolatum (heavy) (250 g), wool fat (200 g), and enough white petrolatum to reach 1000 g.
  • a pharmaceutically effective amount of an agent disclosed herein zinc oxide (50 g), calamine (50 g), liquid petrolatum (heavy) (250 g), wool fat (200 g), and enough white petrolatum to reach 1000 g.
  • the white petrolatum and wool fat are melted and 100 g of liquid petrolatum added thereto.
  • the pharmaceutically effective amount of an agent disclosed herein, zinc oxide, and calamine are added to the remaining liquid petrolatum and the mixture milled until the powders are finely divided and uniformly dispersed.
  • the mixture is stirred into the white petrolatum, melted and cooled with stirring until the ointment congeals.
  • an ointment e.g., an ophthalmic ointment, containing a pharmaceutically effective amount of an agent disclosed herein is prepared from the following types and amounts of ingredients: a pharmaceutically effective amount of an agent disclosed herein, light liquid petrolatum (250 g), wool fat (200 g), and enough white petrolatum to reach 1000 g.
  • the pharmaceutically effective amount of an agent disclosed herein is finely divided and added to the light liquid petrolatum.
  • the wool fat and white petrolatum are melted together, strained, and the temperature adjusted to 45-50° C.
  • the liquid petrolatum slurry is added, and the ointment stirred until congealed.
  • 1000 ml of an aqueous solution containing a pharmaceutically effective amount of an agent disclosed herein is prepared from the following types and amounts of ingredients: a pharmaceutically effective amount of an agent disclosed herein, polyethylene glycol 4000 (120 g) myristyl-gamma-picolinium chloride (0.2 g), polyvinylpyrrolidone (1 g), and enough deionized water to reach 1000 milliliters. Briefly, the ingredients are dissolved in the water and the resulting solution is sterilized by filtration.
  • 1000 g of lotion containing a pharmaceutically effective amount of an agent disclosed herein is prepared from the following types and amounts of ingredients: a pharmaceutically effective amount of an agent disclosed herein, N-methyl pyrolidone (40 g), and enough propylene glycol to reach 1000 g.
  • an aerosol containing a pharmaceutically effective amount of an agent disclosed herein is prepared from the following types and amounts of materials: a pharmaceutically effective amount of an agent disclosed herein, absolute alcohol (4.37 g), Dichlorodifluoroethane (1.43 g) and dichlorotetrafluoroethane (5.70 g). Briefly, the pharmaceutically effective amount of an agent disclosed herein is dissolved in the absolute alcohol and the resulting solution filtered to remove particles and lint. This solution is chilled to about -30° C. Then, to this is added the chilled mixture of dichlorodifluoromethane and dichlorotetrafluoroethane.
  • Gelatin capsules or liquid-filled soft gelatin capsules can contain the active ingredient and powdered or liquid carriers, such as lactose, lecithin starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar-coated or film-coated to mask any unpleasant taste and to protect the tablet from the atmosphere, or enteric-coated for selective, targeted disintegration in the gastrointestinal tract.
  • Liquid dosage forms for oral administration can contain coloring and/or flavoring to increase patient acceptance.
  • parenteral solutions preferably contain about 5-15% polysorbate 80 or lecithin, suitable stabilizing agents and, if necessary, buffer substances.
  • suitable stabilizing agents such as, but not limited to, sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents.
  • citric acid and its salts, and sodium EDTA are suitable stabilizing agents.
  • parenteral solutions can contain preservatives including, but not limited to, benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.
  • kits comprise one or more specific compositions and/or pharmaceutical compositions disclosed herein.
  • the kit further contains printed instructions as a label or package insert directing the use of such reagents to modify skin pigmentation, i.e., to lighten skin as appropriate to the particular included
  • compositions are provided in a container designed to prevent contamination, minimize evaporation or drying of the composition, etc.
  • the compounds may or may not be provided in a preset unit dose or usage amount.
  • An effective amount of a compound as in Formulae I-VIIc may be admixed as a dry powder with a dry gelatin binder in an approximate 1 :2 weight ratio.
  • a minor amount of magnesium stearate may be added as a lubricant.
  • the mixture may then be formed into 240-270 mg tablets (80-90 mg of active compound per tablet) in a tablet press.
  • An effective amount of a compound as in Formulae I-VIIc may be admixed as a dry powder with a starch diluent in an approximate 1 : 1 weight ratio. The mixture may then be filled into 250 mg capsules (125 mg of active compound per capsule).
  • An effective amount of a compound as in Formulae I-VIIc may be admixed with sucrose (1.75 g) and xanthan gum (4 mg) and the resultant mixture may be blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of microcrystalline cellulose and sodium carboxymethyl cellulose (11 :89, 50 mg) in water.
  • Sodium benzoate (10 mg) flavor, and color are diluted with water and added with stirring. Sufficient water may then be added to produce a total volume of 5 mL.
  • An effective amount of a compound as in Formulae I-VIIc may be admixed as a dry powder with a dry gelatin binder in an approximate 1 :2 weight ratio. A minor amount of magnesium stearate may then be added as a lubricant. The mixture may then be formed into 450- 900 mg tablets (150-300 mg of active compound) in a tablet press.
  • An effective amount of a compound as in Formulae I-VIIc may be dissolved or suspended in a buffered sterile saline injectable aqueous medium to a concentration of approximately 5 mg/mL.
  • Stearyl alcohol (250 g) and a white petrolatum (250 g) may be melted at about
  • a mixture of a compound as in Formulae I-VIIc (10-50 g of active compound) methylparaben (0.25 g), propylparaben (0.15 g), sodium lauryl sulfate (10 g), and propylene glycol (120 g) dissolved in water (about 370 g) may then be added and the resulting mixture is stirred until it congeals.
  • the benzopyran compounds as in Formulae I-VIIc which comprise various known drugs or drug like molecules can be purchased from commercial sources and tested for their activities.
  • the benzopyran compounds which are not commercially available can be prepared from readily available starting materials using various general methods and procedures known in the art.
  • the Spectrum Collection library consisting of 2000 drug compounds or natural products represents a source for the identification of compounds useful in the present invention.
  • the library may be screened to identify novel pigmentation inhibitors in cultured murine melanocytes (melan-a).
  • Compounds are dissolved in dimethylsulfoxide (DMSO) to a final concentration of 10 mM. Screening is performed with cultured melanocytes in 24-well plates followed by melanin assay (see below). A minimum change of 50% in melanin formation is established as significant for a pigmentation inhibitor.
  • DMSO may be used as a negative control and the widely used depigmenting agent, hydroquinone, may be used as a positive control on every plate.
  • Primary screening is performed at a final concentration of 1 ⁇ and potential candidates from the primary screening are reconfirmed in duplicate at final concentrations of 1 and 5 ⁇ .
  • Melan-a cells are plated at 5xl0 4 cells per well in 1 ml of culture media in 24-well plates the day before adding the library compounds. All compounds are added at the indicated final concentrations. Cells are harvested after 72 hours of incubation, and the melanin assay is performed.
  • the compounds may be purchased from Sigma, MicroSource or other known suppliers.
  • the compounds are dissolved in dimethylsulfoxide (DMSO) to a final concentration of 10 mM, and are tested for their effect on melanin synthesis at the indicated final concentrations.
  • DMSO dimethylsulfoxide
  • EDTA 150 mM NaCl, pH 7.5) containing a complete protease inhibitor cocktail (Roche).
  • the lysates were centrifuged at 14,000 rpm for 10 minutes at 4 °C.
  • BCA protein assay kit (Pierce) was used to measure the protein concentrations of the supernatants, and bovine serum albumin was used as a standard.
  • the remaining pellets were incubated with 100 ⁇ ethanol-ether (1 : 1) for 10 minutes at room temperature. After removing the ethanol-ether, the pellets were dissolved in 200 ⁇ of 2N NaOH in 20% DMSO at 70 °C. A 180- ⁇ 1 aliquot of the resulting solution was measured for absorbance at 490 nm.
  • the melanin contents were normalized to the total amount of protein.
  • melan-a cells were plated, allowed to attach overnight then dosed with the appropriate concentration of the respective compound. Each concentration was tested in triplicate. After 72 hours, plates were inverted and gently tapped to remove all the media. Fresh media containing MTT reagent (CellTiter, Promega, Madison, WI) was added and incubated per manufacturer's instructions. Absorbance was then measured at 490nm. Values were corrected by subtracting the blank (no cells in the well), and viability was expressed as a function of the viability of cells treated with vehicle alone.
  • MTT reagent CellTiter, Promega, Madison, WI
  • the compounds of the invention may be tested in the MelanodermTM pigmentation assay, to confirm and demonstrate their activity as inhibitors in a setting that replicates in vivo conditions.
  • MelanoDermTM made by MatTek Corp., is a viable reconstituted three-dimensional human skin equivalent containing normal melanocytes and keratinocytes that are derived from African-American (MEL-B), Asian (MEL-A) or Caucasian (MEL-C) donors. Both MEL-A and MEL-B tissues are used in the study, and they are maintained in the NMM-113 medium as recommended by the manufacturer.
  • test compound is dissolved in 30% ethanol: 70 % propylene glycol to a final concentration of 1.0 mm (equal to 356.6 ⁇ g/ml), and this is maintained constant and used on all samples tested.
  • a 25 ⁇ of its aliquot is applied topically to the MelanoDermTM tissue (MEL-B) on Days 0, 1, 3, 6, 8 and 10.
  • the MelanoDermTM tissues are fed every other day with 5 ml fresh NMM-113. Prior to each application, the tissues are washed with 1 ml PBS to remove any residual test compound. Tissues are fixed on Days 10 and 13 for microscopic analysis and histological evaluation. In addition, duplicate tissues are frozen on Days 10 and 13 for the melanin assay.
  • Procedure 1 the effects of the inventive compounds or extract on melanin synthesis in MEL-A or B are evaluated by light microscopy (views from the top surface of the tissue).
  • Procedure 2 the distribution of melanin in the treated-MEL-A or B is accessed by image analysis using Fontana-Masson stained histological sections (views from the side of the tissue).
  • the melanin content of each individual tissue is determined, and the final data show the average melanin content of 2 tissues treated under identical conditions.
  • Melan-a cells are plated at 5xl0 4 cells per well in 1 ml of culture media in 24-well plates the day before adding an extract made from a powder prepared from the fruit of Madura pomifera. Ethanol (70%) is used as control and the extract derived from the fruit of Madura pomifera is diluted in cell culture media at the indicated concentrations. Cells are harvested after 72 hours of incubation, and spectrophotometric melanin assay is performed on cell pellets. The melanin contents are normalized to the total amount of protein. Cell viability is determined by using the CellTiter 96 aqueous nonradioactive cell proliferation assay.
  • Those compounds which are found to reduce pigmentation (melanogenesis modifiers or inhibitors; see Table 1 ,) and compositions thereof can be used as topical agents for hair, fur, and/or feather lightening as required.
  • a melanogenesis inhibitor of the invention or a composition thereof may be applied to sites of hyperpigmentation including, without limitation, age spots, freckles, and chloasma.
  • body lightening or whitening of larger skin zones is a cosmetic objective that can be achieved with a more generalized application of a melanogenesis inhibitor of the invention or a composition thereof.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés de benzopyran de formule I, par exemple, pomiférine-3', 4 '-diméthyle éther, et l'utilisation de ces composés et des compositions associées pour moduler (par exemple inhiber) la mélanogenèse et la pigmentation. R3, R4, R5, R6, R7 et R8 sont tels que décrits dans le descriptif. L'invention concerne également des extraits végétaux contenant un composé de formule I, ainsi que l'utilisation d'un tel extrait de plante pour moduler (par exemple, inhiber) la mélanogenèse et la pigmentation. Le composé ou l'extrait de plante peut être préparé comme compositions pharmaceutiques ou cosmétiques, et peut servir dans la prévention et le traitement d'états se rapportant à une activité aberrante de la mélanogenèse.
PCT/US2012/022994 2011-01-27 2012-01-27 Composés du benzopyran comme modificateurs de la mélanogenèse et utilisations associées WO2012103493A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161436889P 2011-01-27 2011-01-27
US61/436,889 2011-01-27

Publications (1)

Publication Number Publication Date
WO2012103493A1 true WO2012103493A1 (fr) 2012-08-02

Family

ID=46581195

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/022994 WO2012103493A1 (fr) 2011-01-27 2012-01-27 Composés du benzopyran comme modificateurs de la mélanogenèse et utilisations associées

Country Status (1)

Country Link
WO (1) WO2012103493A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356929A (en) * 1989-01-23 1994-10-18 Lehigh University Reduced and quaternized psoralens as photo-activated therapeutics
US20030125264A1 (en) * 2001-12-29 2003-07-03 Kimberly-Clark Worldwide, Inc. Methods For Treating Wounds
US20080045478A1 (en) * 2004-08-10 2008-02-21 Merck Patent Gmbh Flavonoid Complexes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356929A (en) * 1989-01-23 1994-10-18 Lehigh University Reduced and quaternized psoralens as photo-activated therapeutics
US20030125264A1 (en) * 2001-12-29 2003-07-03 Kimberly-Clark Worldwide, Inc. Methods For Treating Wounds
US20080045478A1 (en) * 2004-08-10 2008-02-21 Merck Patent Gmbh Flavonoid Complexes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHANG. ET AL., AN UPDATED REVIEW OF TYROSINASE INHIBITORS IN MOLECULAR SCIENCES, vol. 10, 2009, pages 2440 - 2475 *
LEE ET AL.: "Prenylated Flavonoids as Tyrosinase Inhibitors.", ARCH. PHARM. RES., vol. 27, 2004, pages 1132 - 1135 *

Similar Documents

Publication Publication Date Title
WO2011046978A2 (fr) Composés stéroïdes en tant que modificateurs de la mélanogenèse et leurs utilisations
EP1570839B1 (fr) Composition pour une preparation destinee a un usage externe sur la peau, et methode d'utilisation s'y rapportant
US8563754B2 (en) Compounds, compositions and methods for preventing skin darkening
US20100093823A1 (en) Steroidal compounds as melanogenesis modifiers and uses thereof
US9822125B2 (en) Benzopyran compounds as melanogenesis modifiers and uses thereof
US8772252B2 (en) Coumarin compounds as melanogenesis modifiers and uses thereof
US6878381B2 (en) Resorcinol composition
KR100742267B1 (ko) 서장채국화 추출물, 이의 제조 방법 및 이를 유효성분으로 함유하는 미백용 화장료 조성물
TWI523666B (zh) 包含歐洲百合萃取物之組成物及其用途（二）
US20090298868A1 (en) Quinoline compounds as melanogenesis modifiers and uses thereof
WO2009064493A1 (fr) Composés tricycliques en tant que modificateurs de la mélanogenèse et leurs utilisations
JP2003160461A (ja) 皮膚外用剤
WO2020127888A2 (fr) Composition et formulation de peau d'assombrissement urbain
JP5236335B2 (ja) ラノスタ−８−エン誘導体およびこれらを含有する皮膚外用剤
US9138433B2 (en) Indole alkaloid compounds as melanogenesis promoters and uses thereof
BG65146B1 (bg) Фармацевтичен състав за външно приложение и използването му за избелване на кожата или за намаляване на пигментацията при човек
WO2012103493A1 (fr) Composés du benzopyran comme modificateurs de la mélanogenèse et utilisations associées
KR101553032B1 (ko) 니아졸을 함유하는 피부 미백용 조성물
KR101048477B1 (ko) 인돌알칼로이드계 화합물을 함유하는 피부 미백용 조성물
JP2010515725A (ja) アルテミシニンを含む皮膚美白用組成物
JP2003063944A (ja) 皮膚外用剤及びメラニン生成抑制剤
JP2006241009A (ja) 美白用皮膚外用剤
KR20090039978A (ko) 반대해 추출물을 함유하는 피부 미백 및 항산화 조성물
JP2010070497A (ja) セラミド産生促進剤、保湿剤及び皮膚外用剤
JP2003226649A (ja) メラニン産生不全症予防治療剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12738716

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12738716

Country of ref document: EP

Kind code of ref document: A1